CancerPPD 2.0 - Browse by Length

Browsing by Length

Browse Results:

Filter by Year
From
Upto

ID	PMID	YEAR	Sequence	Name	Length	Linear/Cyclic	Chirality	Chem-MOD	C-ter MOD	N-ter MOD	Nature	Origin	Cell Line	Cancer Type	Assay	Activity	Testing Time	Tissue Affected	Patents
7713	38319435	2024	FFFLSRIF	Temporin-SHf	8	Linear	L	None	Amidation	Free	Antimicrobial	Pelophylax saharica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 32.64 ± 1.350 µM	24-h	Liver	None
7712	38319435	2024	FFFLSRIF	Temporin-SHf	8	Linear	L	None	Amidation	Free	Antimicrobial	Pelophylax saharica	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 36.67 ± 0.729 µM	24-h	Prostate	None
7711	38319435	2024	FFFLSRIF	Temporin-SHf	8	Linear	L	None	Amidation	Free	Antimicrobial	Pelophylax saharica	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 32.76 ± 1.528 µM	24-h	Breast	None
7710	38319435	2024	FFFLSRIF	Temporin-SHf	8	Linear	L	None	Amidation	Free	Antimicrobial	Pelophylax saharica	A-549	Lung Cancer	MTT assay	IC₅₀ = 24.03 ± 0.945 µM	24-h	Lung	None
7702	38272230	2024	RPPLVIC	RP7 SCR	7	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 128 ± 11.65 µM	24-h	Prostate	None
7703	38272230	2024	RPPLVIC	RP7 SCR	7	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	DU-145	Prostate Cancer	MTT assay	IC₅₀ = 137 ± 5.98 µM	24-h	Prostate	None
7701	38272230	2024	RPPLVIC	RP7 SCR	7	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 150 ± 10.32 µM	24-h	Breast	None
7700	38272230	2024	RPPLVIC	RP7 SCR	7	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 156 ± 8.15 µM	24-h	Breast	None
7699	38272230	2024	rppcvil	D-RP-7	7	Linear	D	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	DU-145	Prostate Cancer	MTT assay	IC₅₀ = 121.59 ± 6.56 µM	24-h	Prostate	None
7698	38272230	2024	rppcvil	D-RP-7	7	Linear	D	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 101 ± 5.73 µM	24-h	Prostate	None
7696	38272230	2024	rppcvil	D-RP-7	7	Linear	D	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 95 ± 7.71 µM	24-h	Breast	None
7697	38272230	2024	rppcvil	D-RP-7	7	Linear	D	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 90 ± 10.31 µM	24-h	Breast	None
7694	38272230	2024	RPPCVIL	RP-7	7	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 113 ± 8.02 µM	24-h	Prostate	None
7695	38272230	2024	RPPCVIL	RP-7	7	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	DU-145	Prostate Cancer	MTT assay	IC₅₀ = 120.72 ± 7.08 µM	24-h	Prostate	None
7693	38272230	2024	RPPCVIL	RP-7	7	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 110.12 ± 4.23 µM	24-h	Breast	None
7691	38272230	2024	LAKAVI	LA3IK-SCR	6	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	DU-145	Prostate Cancer	MTT assay	IC₅₀ = 351.76 ± 7.18 µM	24-h	Prostate	None
7692	38272230	2024	RPPCVIL	RP-7	7	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 139.03 ± 8.41 µM	24-h	Breast	None
7690	38272230	2024	LAKAVI	LA3IK-SCR	6	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 319 ± 13.64 µM	24-h	Prostate	None
7689	38272230	2024	LAKAVI	LA3IK-SCR	6	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 133 ± 9.52 µM	24-h	Breast	None
7688	38272230	2024	LAKAVI	LA3IK-SCR	6	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 243 ± 8.16 µM	24-h	Breast	None
7686	38272230	2024	laiavk	D-LA3IK	6	Linear	D	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 98.71 ± 6.17 µM	24-h	Prostate	None
7687	38272230	2024	laiavk	D-LA3IK	6	Linear	D	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	DU-145	Prostate Cancer	MTT assay	IC₅₀ = 89.11 ± 8.12 µM	24-h	Prostate	None
7685	38272230	2024	laiavk	D-LA3IK	6	Linear	D	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 91.2 ± 8.21 µM	24-h	Breast	None
7683	38272230	2024	LAIAVK	LA3IK	6	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	DU-145	Prostate Cancer	MTT assay	IC₅₀ = 335.7 ± 3.09 µM	24-h	Prostate	None
7684	38272230	2024	laiavk	D-LA3IK	6	Linear	D	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 197.72 ± 5.42 µM	24-h	Breast	None
7681	38272230	2024	LAIAVK	LA3IK	6	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 90.23 ± 7.32 µM	24-h	Breast	None
7682	38272230	2024	LAIAVK	LA3IK	6	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 321.4 ± 11.79 µM	24-h	Prostate	None
7680	38272230	2024	LAIAVK	LA3IK	6	Linear	L	None	Amidation	Acetylation	Anticancer	Migration and invasion enhancer 1 (MIEN1)	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 223.6 ± 5.62 µM	24-h	Breast	None
7658	37298595	2023	PEGKRPY-Tle-L	NT-12	9	Linear	L	Tle = L-tert-leucine	Free	Free	Anticancer	Synthetic analogue of Neurotensin	HCT-116	Colorectal Cancer	MTS assay	Not Available	24-h	Colon	None
7659	37298595	2023	PEGKKPY-Tle-L	NT-12	9	Linear	L	Tle = L-tert-leucine	Free	Free	Anticancer	Synthetic analogue of Neurotensin	HCT-116	Colorectal Cancer	MTS assay	Not Available	24-h	Colon	None
7656	37298595	2023	RRPYAL	NT-11	6	Linear	L	None	Free	Free	Anticancer	Synthetic analogue of Neurotensin	HCT-116	Colorectal Cancer	MTS assay	Not Available	24-h	Colon	None
7657	37298595	2023	PEGRKPY-Tle-L	NT-12	9	Linear	L	Tle = L-tert-leucine	Free	Free	Anticancer	Synthetic analogue of Neurotensin	HCT-116	Colorectal Cancer	MTS assay	Not Available	24-h	Colon	None
7654	37298595	2023	RRPYIL	NT-9	6	Linear	L	None	Free	Free	Anticancer	Synthetic analogue of Neurotensin	HCT-116	Colorectal Cancer	MTS assay	Not Available	24-h	Colon	None
7655	37298595	2023	RRPAIL	NT-10	6	Linear	L	None	Free	Free	Anticancer	Synthetic analogue of Neurotensin	HCT-116	Colorectal Cancer	MTS assay	Not Available	24-h	Colon	None
7609	34986732	2023	trans(P)PIPYPIF	trans-Phakellistatin 18	7	Cyclic	L	Proline residues in trans-configuration	Free	Free	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 67.5 ± 2.938 µM	Not Available	Liver	None
7590	37380046	2023	ATRQPNH	RP7	7	Linear	L	None	Free	Free	Anticancer	RAGE(receptor for advanced glycation end product) inhibitor	BT-549	Breast Cancer	MTT assay	IC₅₀ = 29.9 µM	48-h	Breast	None
7589	37380046	2023	ATRQPNH	RP7	7	Linear	L	None	Free	Free	Anticancer	RAGE(receptor for advanced glycation end product) inhibitor	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 24.5 µM	48-h	Breast	None
7585	37273629	2023	PSRKVMLWS	PS9	9	Linear	L	None	Free	Free	Anticancer	Aphanomyces invadans	MCF-7	Breast Cancer	LDH leakage assay	71.25 ± 1.3% LDH release at 40 μM	24-h	Breast	None
7584	37273629	2023	PSRKVMLWS	PS9	9	Linear	L	None	Free	Free	Anticancer	Aphanomyces invadans	MCF-7	Breast Cancer	Neutral Red Uptake assay	IC₅₀ value range between 25.27 - 43.28 μM	24-h	Breast	None
7581	37068520	2023	YSFGL	Test peptide	5	Linear	L	None	Amidation	Free	Anti cancer	Neuropep Peptide	A-549	Lung Cancer	MTT assay	IC₅₀ = 26.417±0.660 µM	48 h	Lung	None
7582	37068520	2023	YSFGL	Test peptide	5	Linear	L	None	Amidation	Free	Anti cancer	Neuropep Peptide	MDA-MB-231	Lung Cancer	MTT assay	IC₅₀ = 39.047±0.770 µM	48 h	Lung	None
7577	36168817	2023	NDGNQPL	Rapeseed peptide	7	Linear	L	None	Free	Free	Anticancer	extracted from rapeseed protein	HepG-2	Liver Cancer	Apoptosis assay	28.39 ± 0.80% apoptosis rate at 0.5 mmol/L	NA	Liver	None
7576	36168817	2023	NDGNQPL	Rapeseed peptide	7	Linear	L	None	Free	Free	Anticancer	extracted from rapeseed protein	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 1.56 mmol/L	24-h	Liver	None
7534	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 18	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	decanoyl	Antitubercular	Trichoderin A	PANC-1	Pancreatic Cancer	CyQUANT Direct assay	IC₅₀ = 0.2 μM	24-h	Pancreas	None
7535	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 19	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	dodecanoyl	Antitubercular	Trichoderin A	PANC-1	Pancreatic Cancer	CyQUANT Direct assay	IC₅₀ = 0.2 μM	24-h	Pancreas	None
7533	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 17	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Octanoyl	Antitubercular	Trichoderin A	PANC-1	Pancreatic Cancer	CyQUANT Direct assay	IC₅₀ = 0.6 μM	24-h	Pancreas	None
7532	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 16	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Hexanoyl	Antitubercular	Trichoderin A	PANC-1	Pancreatic Cancer	CyQUANT Direct assay	IC₅₀ = 0.5 μM	24-h	Pancreas	None
7530	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 14	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Propanoyl	Antitubercular	Trichoderin A	PANC-1	Pancreatic Cancer	CyQUANT Direct assay	IC₅₀ = 1.8 μM	24-h	Pancreas	None
7531	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 15	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Butanoyl	Antitubercular	Trichoderin A	PANC-1	Pancreatic Cancer	CyQUANT Direct assay	IC₅₀ = 0.9 μM	24-h	Pancreas	None
7529	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 13	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Ethanoyl	Antitubercular	Trichoderin A	PANC-1	Pancreatic Cancer	CyQUANT Direct assay	IC₅₀ = 6.0 μM	24-h	Pancreas	None
7528	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 12	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Free	Antitubercular	Trichoderin A	PANC-1	Pancreatic Cancer	CyQUANT Direct assay	IC₅₀ > 9 μM	24-h	Pancreas	None
7525	36678914	2023	MDA-P-AHMOD-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 19	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	dodecanoyl	Antitubercular	Trichoderin A	BxPC-3	Pancreatic Cancer	PrestoBlue assay	IC₅₀ = 0.1 μM	24-h	Pancreas	None
7524	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 18	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	decanoyl	Antitubercular	Trichoderin A	BxPC-3	Pancreatic Cancer	PrestoBlue assay	IC₅₀ = 0.2 μM	24-h	Pancreas	None
7523	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 17	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid; AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Octanoyl	Antitubercular	Trichoderin A	BxPC-3	Pancreatic Cancer	PrestoBlue assay	IC₅₀ = 0.4 μM	24-h	Pancreas	None
7522	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 16	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Hexanoyl	Antitubercular	Trichoderin A	BxPC-3	Pancreatic Cancer	PrestoBlue assay	IC₅₀ = 0.4 μM	24-h	Pancreas	None
7521	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 15	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Butanoyl	Antitubercular	Trichoderin A	BxPC-3	Pancreatic Cancer	PrestoBlue assay	IC₅₀ = 0.5 μM	24-h	Pancreas	None
7519	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 13	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Ethanoyl	Antitubercular	Trichoderin A	BxPC-3	Pancreatic Cancer	PrestoBlue assay	IC₅₀ > 1 μM	24-h	Pancreas	None
7520	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 14	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Propanoyl	Antitubercular	Trichoderin A	BxPC-3	Pancreatic Cancer	PrestoBlue assay	IC₅₀ = 0.6 μM	24-h	Pancreas	None
7518	36678914	2023	P-Cha-Aib-Aib-IV-Aib-Aib-AMAE	trichoderin A analogue 12	9	Linear	L	AHMOD replaced by Cha(L-cyclohexylalanine); MDA = 2-methyl decanoic acid; Aib = a-aminoisobutyric acid;AMAE = 2-[(20-aminopropyl) methylamino] ethanol	Free	Free	Antitubercular	Trichoderin A	BxPC-3	Pancreatic Cancer	PrestoBlue assay	IC₅₀ > 1 μM	24-h	Pancreas	None
7477	36687035	2023	WQWRWQWR	1-R	8	Linear	L	None	Amidation	Free	Antibacterial and Anticancer	Synthetic analogue of LfcinB(21-25)Pal	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 130 µM	24-h	Breast	None
7478	36687035	2023	WQWRWQWR	1-R	8	Linear	L	None	Amidation	Free	Antibacterial and Anticancer	Synthetic analogue of LfcinB(21-25)Pal	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ > 150 µM	24-h	Breast	None
7476	36687035	2023	RWQWRWQW	R-1	8	Linear	L	None	Amidation	Free	Antibacterial and Anticancer	Synthetic analogue of LfcinB(21-25)Pal	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ > 150 µM	24-h	Breast	None
7475	36687035	2023	RWQWRWQW	R-1	8	Linear	L	None	Amidation	Free	Antibacterial and Anticancer	Synthetic analogue of LfcinB(21-25)Pal	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 58 µM	24-h	Breast	None
7473	36687035	2023	WQWRWQW	1	7	Linear	L	None	Amidation	Free	Antibacterial and Anticancer	Synthetic analogue of LfcinB(21-25)Pal	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 105 µM	24-h	Breast	None
7474	36687035	2023	WQWRWQW	1	7	Linear	L	None	Amidation	Free	Antibacterial and Anticancer	Synthetic analogue of LfcinB(21-25)Pal	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ > 170 µM	24-h	Breast	None
7466	36687035	2023	RWQWRWQWR	LfcinB(21-25)Pal	9	Linear	L	None	Amidation	Free	Antibacterial and Anticancer	LfcinB	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 81 µM	24-h	Breast	None
7465	36687035	2023	RWQWRWQWR	LfcinB(21-25)Pal	9	Linear	L	None	Amidation	Free	Antibacterial and Anticancer	LfcinB	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 103 µM	24-h	Breast	None
7464	36687035	2023	RWQWRWQWR	LfcinB(21-25)Pal	9	Linear	L	None	Amidation	Free	Antibacterial and Anticancer	LfcinB	MDA-MB-468	Breast Cancer	MTT assay	IC₅₀ = 72 µM	24-h	Breast	None
7434	37867694	2023	rWQWOWQWR	1[^dR] 5[Orn] [Pal]	9	Linear	Mix	O=Ornithine	Amidation	Free	Anticancer	Synthetic	CaCo-2	Colorectal Cancer	MTT assay	IC₅₀ = 109 μM	24-h	Colon	None
7433	37867694	2023	RWQWOWQWR	5[Orn] [Pal]	9	Linear	L	O=Ornithine	Amidation	Free	Anticancer	Synthetic	CaCo-2	Colorectal Cancer	MTT assay	IC₅₀ = 64 μM	24-h	Colon	None
7432	37867694	2023	OWQWRWQWR	1[Orn] [Pal]	9	Linear	L	O=Ornithine	Amidation	Free	Anticancer	Synthetic	CaCo-2	Colorectal Cancer	MTT assay	IC₅₀ = 91 μM	24-h	Colon	None
7431	37867694	2023	rWQWRWQWR	1[^dR][Pal]	9	Linear	Mix	None	Amidation	Free	Anticancer	Synthetic	CaCo-2	Colorectal Cancer	MTT assay	IC₅₀ = 105 μM	24-h	Colon	None
7429	37867694	2023	RWQWRWQWO	9[Orn] [Pal]	9	Linear	L	O=Ornithine	Amidation	Free	Anticancer	Synthetic	DU-145	Prostrate Cancer	MTT assay	IC₅₀ = 62 μM	24-h	Prostate	None
7427	37867694	2023	RWQWRWQWO	9[Orn] [Pal]	9	Linear	L	O=Ornithine	Amidation	Free	Anticancer	Synthetic	HT-29	Colon Cancer	MTT assay	IC₅₀ = 109 μM	24-h	Colon	None
7428	37867694	2023	RWQWRWQWO	9[Orn] [Pal]	9	Linear	L	O=Ornithine	Amidation	Free	Anticancer	Synthetic	CaCo-2	Colorectal Cancer	MTT assay	IC₅₀ = 40 μM	24-h	Colon	None
7424	37867694	2023	RWQWRWQWR	LfcinB (21-25)Pal	9	Linear	L	None	Amidation	Free	Anticancer	LfcinB	DU-145	Prostrate Cancer	MTT assay	IC₅₀ = 40 μM	24-h	Prostate	None
7423	37867694	2023	RWQWRWQWR	LfcinB (21-25)Pal	9	Linear	L	None	Amidation	Free	Anticancer	LfcinB	HT-29	Colon Cancer	MTT assay	IC₅₀ = 100 μM	24-h	Colon	None
7422	37867694	2023	RWQWRWQWR	LfcinB (21-25)Pal	9	Linear	L	None	Amidation	Free	Anticancer	LfcinB	CaCo-2	Colorectal Cancer	MTT assay	IC₅₀ = 86 μM	24-h	Colon	None
7368	35889301	2022	LXVLF	Sansalvimide A	5	Cyclic	L	X = OLeu	Cyclized	Cyclized	Anticancer	Fusarium sp.	HCT-116	Colon Cancer	Not Available	IC₅₀ = 9.8 µg/ml	Not Available	Colon	None
7369	35889301	2022	LXVLF	Sansalvimide A	5	Cyclic	L	X = OLeu	Cyclized	Cyclized	Anticancer	Fusarium sp.	Colo-205	Colon Cancer	Not Available	IC₅₀ = 3.5 µg/ml	Not Available	Colon	None
7370	35889301	2022	LXVLF	Sansalvimide A	5	Cyclic	L	X = OLeu	Cyclized	Cyclized	Anticancer	Fusarium sp.	SK-MEL-2	Skin Cancer	Not Available	IC₅₀ = 5.9 µg/ml	Not Available	Skin	None
7296	36713538	2022	KKWWKKW-Dip-K	NTP-217	9	Linear	L	Dip = β-diphenylalanine	Amidation	rhodamine B - GABA	Anticancer	Synthetic	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 40.1 ± 1.3 µM	4-h	Liver	None
7297	36713538	2022	KKWWKKW-Dip-K	NTP-217	9	Linear	L	Dip = β-diphenylalanine	Amidation	rhodamine B - GABA	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 48.8 ± 0.7 µM	4-h	Liver	None
7298	36713538	2022	KKWWKKW-Dip-K	NTP-217	9	Linear	L	Dip = β-diphenylalanine	Amidation	rhodamine B - GABA	Anticancer	Synthetic	Hep3B	Liver Cancer	MTT assay	IC₅₀ = 45.7 ± 1.7 µM	4-h	Liver	None
7293	36713538	2022	KKWWKKW-Dip-K	NTP-217	9	Linear	L	Dip = β-diphenylalanine	Amidation	rhodamine B - GABA	Anticancer	Synthetic	Hepa 1-6	Liver Cancer	MTT assay	IC₅₀ = 21.6 ± 1.0 µM	4-h	Liver	None
7294	36713538	2022	KKWWKKW-Dip-K	NTP-217	9	Linear	L	Dip = β-diphenylalanine	Amidation	rhodamine B - GABA	Anticancer	Synthetic	PLC/PRF/5	Liver Cancer	MTT assay	IC₅₀ = 14.6 ± 1.1 µM	4-h	Liver	None
7295	36713538	2022	KKWWKKW-Dip-K	NTP-217	9	Linear	L	Dip = β-diphenylalanine	Amidation	rhodamine B - GABA	Anticancer	Synthetic	HCCLM-3	Liver Cancer	MTT assay	IC₅₀ = 22.4 ± 5.1 µM	4-h	Liver	None
7273	36186562	2022	EEEEY	C16-E4Y	5	Linear	L	None	Free	Palmitoyl	Anticancer	Synthetic	MCF-7	Breast Cancer	WST-8 assay	50 % cell viability at 0.05 wt %	24-h	Breast	None
7270	36186562	2022	EEEEY	C16-E4Y	5	Linear	L	None	Free	Palmitoyl	Anticancer	Synthetic	A-431	Skin Cancer	WST-8 assay	10 % cell viability at 0.05 wt %	24-h	Skin	None
7271	36186562	2022	EEEEY	C16-E4Y	5	Linear	L	None	Free	Palmitoyl	Anticancer	Synthetic	HeLa	Cervical Cancer	WST-8 assay	60% cell viability at 0.05 wt %	24-h	Cervix	None
7272	36186562	2022	EEEEY	C16-E4Y	5	Linear	L	None	Free	Palmitoyl	Anticancer	Synthetic	HepG-2	Liver Cancer	WST-8 assay	50 % cell viability at 0.05 wt %	24-h	Liver	None
7256	36360120	2022	GPLGAGP	HTDT-6-2-3-2	7	Linear	L	None	Free	Free	Anticancer	Enteromorpha prolifera	HepG-2	Liver Cancer	CCK-8 assay	IC₅₀ = 1.2564 ± 0.0548 mg/mL	48-h	Liver	None
7257	36360120	2022	GPLGAGP	HTDT-6-2-3-2	7	Linear	L	None	Free	Free	Anticancer	Enteromorpha prolifera	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 0.9867 ± 0.0857 mg/mL	48-h	Lung	None
7255	36360120	2022	GPLGAGP	HTDT-6-2-3-2	7	Linear	L	None	Free	Free	Anticancer	Enteromorpha prolifera	NCI-H-460	Lung Cancer	CCK-8 assay	IC₅₀ = 0.3686 ± 0.0935 mg/mL	48-h	Lung	None
7169	35323457	2022	lPlPl	Z-8	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 15.88 ± 1.42 µg/ml	NA	Lung	None
7167	35323457	2022	lPlPl	Z-8	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 20.16 ± 2.24 µg/ml	NA	Breast	None
7168	35323457	2022	lPlPl	Z-8	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 7.97 ± 0.61 µg/ml	NA	Cervix	None
7164	35323457	2022	LPlPl	Z-7	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 9.97 ± 1.00 µg/ml	NA	Lung	None
7165	35323457	2022	lPlPl	Z-8	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 7.82 ± 1.18 µg/ml	NA	Breast	None
7166	35323457	2022	lPlPl	Z-8	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.00 ± 0.83 µg/ml	NA	Liver	None
7162	35323457	2022	LPlPl	Z-7	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 16.52 ± 1.7 µg/ml	NA	Breast	None
7163	35323457	2022	LPlPl	Z-7	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 18.21 ± 1.35 µg/ml	NA	Cervix	None
7160	35323457	2022	LPlPl	Z-7	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 13.28 ± 3.28 µg/ml	NA	Breast	None
7161	35323457	2022	LPlPl	Z-7	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 13.85 ± 1.99 µg/ml	NA	Liver	None
7157	35323457	2022	lPLPl	Z-6	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 4.59 ± 0.27 µg/ml	NA	Breast	None
7158	35323457	2022	lPLPl	Z-6	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 5.69 ± 0.37 µg/ml	NA	Cervix	None
7159	35323457	2022	lPLPl	Z-6	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 5.96 ± 0.41 µg/ml	NA	Lung	None
7155	35323457	2022	lPLPl	Z-6	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 1.65 ± 0.3 µg/ml	NA	Breast	None
7156	35323457	2022	lPLPl	Z-6	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.91 ± 0.17 µg/ml	NA	Liver	None
7153	35323457	2022	LPLPl	Z-5	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 12.12 ± 0.95 µg/ml	NA	Cervix	None
7154	35323457	2022	LPLPl	Z-5	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 9.5 ± 1.13 µg/ml	NA	Lung	None
7150	35323457	2022	LPlPL	Z-4	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 13.43 ± 1.96 µg/ml	NA	Breast	None
7151	35323457	2022	LPLPl	Z-5	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 14.98 ± 0.93 µg/ml	NA	Liver	None
7152	35323457	2022	LPLPl	Z-5	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 8.48 ± 1.12 µg/ml	NA	Breast	None
7148	35323457	2022	LPlPL	Z-4	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 7.38 ± 0.83 µg/ml	NA	Cervix	None
7149	35323457	2022	LPlPL	Z-4	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 9.85 ± 0.95 µg/ml	NA	Lung	None
7145	35323457	2022	lPLPL	Z-3	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 4.88 ± 0.58 µg/ml	NA	Breast	None
7146	35323457	2022	LPlPL	Z-4	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 15.23 ± 1.14 µg/ml	NA	Liver	None
7147	35323457	2022	LPlPL	Z-4	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 22.09 ± 1.12 µg/ml	NA	Breast	None
7143	35323457	2022	lPLPL	Z-3	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 5.57 ± 0.45 µg/ml	NA	Cervix	None
7144	35323457	2022	lPLPL	Z-3	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 6.43 ± 0.43 µg/ml	NA	Lung	None
7141	35323457	2022	lPLPL	Z-3	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 5.05 ± 0.45 µg/ml	NA	Liver	None
7142	35323457	2022	lPLPL	Z-3	5	Cyclic	Mix	None	Cyclized	Cyclized	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 6.34 ± 0.6 µg/ml	NA	Breast	None
7138	35323457	2022	LPLPL	Z-2	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 14.5 ± 0.36 µg/ml	NA	Cervix	None
7139	35323457	2022	LPLPL	Z-2	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 7.97 ± 2.06 µg/ml	NA	Lung	None
7140	35323457	2022	LPLPL	Z-2	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 2.25 ± 0.42 µg/ml	NA	Breast	None
7136	35323457	2022	LPLPL	Z-2	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 11.95 ± 0.64 µg/ml	NA	Liver	None
7137	35323457	2022	LPLPL	Z-2	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 14.45 ± 1.1 µg/ml	NA	Breast	None
7134	35323457	2022	L(N-Me-L)LPL	Z-1	5	Cyclic	L	N-Me-L = N-methyl-Lysine	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 4.92 ± 0.84 µg/ml	NA	Lung	None
7135	35323457	2022	LPLPL	Z-2	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 4.68 ± 1.22 µg/ml	NA	Breast	None
7132	35323457	2022	L(N-Me-L)LPL	Z-1	5	Cyclic	L	N-Me-L = N-methyl-Lysine	Cyclized	Cyclized	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 17.81 ± 0.6 µg/ml	NA	Breast	None
7133	35323457	2022	L(N-Me-L)LPL	Z-1	5	Cyclic	L	N-Me-L = N-methyl-Lysine	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 11.56 ± 0.65 µg/ml	NA	Cervix	None
7130	35323457	2022	L(N-Me-L)LPL	Z-1	5	Cyclic	L	N-Me-L = N-methyl-Lysine	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 5.85 ± 1.28 µg/ml	NA	Breast	None
7131	35323457	2022	L(N-Me-L)LPL	Z-1	5	Cyclic	L	N-Me-L = N-methyl-Lysine	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 7.57 ± 0.17 µg/ml	NA	Liver	None
7128	35323457	2022	(N-Me-L)L(N-Me-L)LL	Galaxamide	5	Cyclic	L	N-Me-L = N-methyl-Lysine	Cyclized	Cyclized	Anticancer	Galaxaura ﬁlamentosa	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 8.73 ± 0.29 µg/ml	NA	Breast	None
7129	35323457	2022	(N-Me-L)L(N-Me-L)LL	Galaxamide	5	Cyclic	L	N-Me-L = N-methyl-Lysine	Cyclized	Cyclized	Anticancer	Galaxaura ﬁlamentosa	A-549	Lung Cancer	MTT assay	IC₅₀ = 6.99 ± 0.63 µg/ml	NA	Lung	None
7126	35323457	2022	(N-Me-L)L(N-Me-L)LL	Galaxamide	5	Cyclic	L	N-Me-L = N-methyl-Lysine	Cyclized	Cyclized	Anticancer	Galaxaura ﬁlamentosa	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 11.33 ± 2.95 µg/ml	NA	Breast	None
7127	35323457	2022	(N-Me-L)L(N-Me-L)LL	Galaxamide	5	Cyclic	L	N-Me-L = N-methyl-Lysine	Cyclized	Cyclized	Anticancer	Galaxaura ﬁlamentosa	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 8.53 ± 0.73 µg/ml	NA	Cervix	None
7125	35323457	2022	(N-Me-L)L(N-Me-L)LL	Galaxamide	5	Cyclic	L	N-Me-L = N-methyl-Lysine	Cyclized	Cyclized	Anticancer	Galaxaura ﬁlamentosa	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 5.20 ± 0.52 µg/ml	NA	Liver	None
6937	36355026	2022	TFKHG	LJP-12	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	H-22	Liver Cancer	MTT assay	IC₅₀ = 0.72 ± 0.05 mM	48-h	Liver	None
6935	36355026	2022	TFKHG	LJP-12	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 0.41 ± 0.04 mM	48-h	Liver	None
6936	36355026	2022	TFKHG	LJP-12	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 0.60 ± 0.08 mM	48-h	Liver	None
6934	36355026	2022	YEHSHG	LJP-11	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	H-22	Liver Cancer	MTT assay	IC₅₀ = 0.70 ± 0.07 mM	48-h	Liver	None
6933	36355026	2022	YEHSHG	LJP-11	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 0.61 ± 0.07 mM	48-h	Liver	None
6931	36355026	2022	HASWEH	LJP-10	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	H-22	Liver Cancer	MTT assay	IC₅₀ = 3.53 ± 0.34 mM	48-h	Liver	None
6932	36355026	2022	YEHSHG	LJP-11	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 0.49 ± 0.05 mM	48-h	Liver	None
6930	36355026	2022	HASWEH	LJP-10	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.69 ± 0.22 mM	48-h	Liver	None
6928	36355026	2022	FEHSG	LJP-9	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	H-22	Liver Cancer	MTT assay	IC₅₀ = 0.51 ± 0.07 mM	48-h	Liver	None
6929	36355026	2022	HASWEH	LJP-10	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 3.52 ± 0.35 mM	48-h	Liver	None
6927	36355026	2022	FEHSG	LJP-9	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 0.69 ± 0.08 mM	48-h	Liver	None
6925	36355026	2022	FSHTYV	LJP-8	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	H-22	Liver Cancer	MTT assay	IC₅₀ = 0.76 ± 0.08 mM	48-h	Liver	None
6926	36355026	2022	FEHSG	LJP-9	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 0.53 ± 0.05 mM	48-h	Liver	None
6924	36355026	2022	FSHTYV	LJP-8	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 0.63 ± 0.05 mM	48-h	Liver	None
6923	36355026	2022	FSHTYV	LJP-8	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 0.44 ± 0.04 mM	48-h	Liver	None
6921	36355026	2022	HAGYSWA	LJP-7	7	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 1.66 ± 0.11 mM	48-h	Liver	None
6922	36355026	2022	HAGYSWA	LJP-7	7	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	H-22	Liver Cancer	MTT assay	IC₅₀ = 1.44 ± 0.12 mM	48-h	Liver	None
6920	36355026	2022	HAGYSWA	LJP-7	7	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 2.53 ± 0.24 mM	48-h	Liver	None
6918	36355026	2022	FSTHGG	LJP-5	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	H-22	Liver Cancer	MTT assay	IC₅₀ = 1.49 ± 0.13 mM	48-h	Liver	None
6919	36355026	2022	FKEHGY	LJP-6	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 3.06 ± 0.31 mM	48-h	Liver	None
6917	36355026	2022	FSTHGG	LJP-5	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.78 ± 0.26 mM	48-h	Liver	None
6915	36355026	2022	EGHGF	LJP-4	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	H-22	Liver Cancer	MTT assay	IC₅₀ = 0.68 ± 0.07 mM	48-h	Liver	None
6916	36355026	2022	FSTHGG	LJP-5	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 2.44 ± 0.22 mM	48-h	Liver	None
6914	36355026	2022	EGHGF	LJP-4	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 0.65 ± 0.07 mM	48-h	Liver	None
6912	36355026	2022	FSHRGH	LJP-3	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	H-22	Liver Cancer	MTT assay	IC₅₀ = 1.70 ± 0.15 mM	48-h	Liver	None
6913	36355026	2022	EGHGF	LJP-4	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 0.62 ± 0.07 mM	48-h	Liver	None
6911	36355026	2022	FSHRGH	LJP-3	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 1.42 ± 0.12 mM	48-h	Liver	None
6909	36355026	2022	LWEHSH	LJP-2	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 1.71 ± 0.13 mM	48-h	Liver	None
6910	36355026	2022	LWEHSH	LJP-2	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	H-22	Liver Cancer	MTT assay	IC₅₀ = 0.62 ± 0.05 mM	48-h	Liver	None
6908	36355026	2022	LWEHSH	LJP-2	6	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 2.25 ± 0.22 mM	48-h	Liver	None
6906	36355026	2022	EGFHL	LJP-1	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 0.45 ± 0.05 mM	48-h	Liver	None
6907	36355026	2022	EGFHL	LJP-1	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	H-22	Liver Cancer	MTT assay	IC₅₀ = 0.36 ± 0.03 mM	48-h	Liver	None
6905	36355026	2022	EGFHL	LJP-1	5	Linear	L	None	Free	Free	Anticancer	Laminaria japonica	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 0.48 ± 0.05 mM	48-h	Liver	None
6853	33567789	2021	KnLAKnLAK	Si15	7	Linear	L	nL = nor-Leu	Amidation	Caffeic acid (Caf)	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 140.3 ± 7.12 µM	72-h	Breast	None
6854	33567789	2021	KnLAKnLAK	Si15	7	Linear	L	nL = nor-Leu	Amidation	Caffeic acid (Caf)	Antimicrobial and Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 346.3 ± 7.91 µM	72-h	Breast	None
6851	33567789	2021	KnLAKnLAK	Si14	7	Linear	L	nL = nor-Leu	Amidation	1,8-naphthalimide-Gly	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 593.3 ± 60.3 µM	72-h	Breast	None
6852	33567789	2021	KnLAKnLAK	Si14	7	Linear	L	nL = nor-Leu	Amidation	1,8-naphthalimide-Gly	Antimicrobial and Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 1049 ± 49.77 µM	72-h	Breast	None
6849	33567789	2021	KL(Beta-A)KL(Beta-A)K	Si11	7	Linear	L	β-Ala	Amidation	Caffeic acid (Caf)	Antimicrobial and Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 1087 ± 70.71 µM	72-h	Breast	None
6850	33567789	2021	KnLAKnLAK	Si13	7	Linear	L	nL = nor-Leu	Amidation	Free	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 1704 ± 112 µM	72-h	Breast	None
6847	33567789	2021	KL(Beta-A)KL(Beta-A)K	Si2	7	Linear	L	β-Ala	Amidation	1,8-naphthalimide-Gly	Antimicrobial and Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 840 ± 21.18 µM	72-h	Breast	None
6848	33567789	2021	KL(Beta-A)KLAK	Si11	7	Linear	L	β-Ala	Amidation	Caffeic acid (Caf)	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 228.8 ± 7.18 µM	72-h	Breast	None
6846	33567789	2021	KL(Beta-A)KL(Beta-A)K	Si2	7	Linear	L	β-Ala	Amidation	1,8-naphthalimide-Gly	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 662.9 ± 20.02 µM	72-h	Breast	None
6844	33567789	2021	KLAKLAK	Si8	7	Linear	L	None	Amidation	Caffeic acid (Caf)	Antimicrobial and Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 514.3 ± 26.82 µM	72-h	Breast	None
6845	33567789	2021	KL(Beta-A)KL(Beta-A)AK	Si3	8	Linear	L	β-Ala	Amidation	Free	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 176.3 ± 4.66 µM	72-h	Breast	None
6842	33567789	2021	KLAKLAK	Si7	7	Linear	L	None	Amidation	1,8-naphthalimide-Gly	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 1195 ± 131.5 µM	72-h	Breast	None
6843	33567789	2021	KLAKLAK	Si8	7	Linear	L	None	Amidation	Caffeic acid (Caf)	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 128.6 ± 8.03 µM	72-h	Breast	None
6774	33462944	2021	FSHTYV	GP-3	6	Linear	L	None	Amidation	Free	Anticancer	Ginseng Leaf Peptide	Colo-320	Colon Cancer	MTT assay	IC₅₀ = 149 ± 15.2 µM	48-h	Colon	None
6772	33462944	2021	FSHTYV	GP-3	6	Linear	L	None	Amidation	Free	Anticancer	Ginseng Leaf Peptide	CT-26	Colorectal Cancer	MTT assay	IC₅₀ = 133 ± 12.5 µM	48-h	Colon	None
6773	33462944	2021	FSHTYV	GP-3	6	Linear	L	None	Amidation	Free	Anticancer	Ginseng Leaf Peptide	CaCo-2	Colon Cancer	MTT assay	IC₅₀ = 162 ± 17.1 µM	48-h	Colon	None
6770	33462944	2021	EGFHL	GP-2	5	Linear	L	None	Amidation	Free	Anticancer	Ginseng Leaf Peptide	CaCo-2	Colon Cancer	MTT assay	IC₅₀ = 154 ± 15.8 µM	48-h	Colon	None
6771	33462944	2021	EGFHL	GP-2	5	Linear	L	None	Amidation	Free	Anticancer	Ginseng Leaf Peptide	Colo-320	Colon Cancer	MTT assay	IC₅₀ = 142 ± 14.9 µM	48-h	Colon	None
6768	33462944	2021	FKEHGY	GP-1	6	Linear	L	None	Amidation	Free	Anticancer	Ginseng Leaf Peptide	Colo-320	Colon Cancer	MTT assay	IC₅₀ = 111 ± 12.0 µM	48-h	Colon	None
6769	33462944	2021	EGFHL	GP-2	5	Linear	L	None	Amidation	Free	Anticancer	Ginseng Leaf Peptide	CT-26	Colorectal Cancer	MTT assay	IC₅₀ = 114 ± 12.1 µM	48-h	Colon	None
6767	33462944	2021	FKEHGY	GP-1	6	Linear	L	None	Amidation	Free	Anticancer	Ginseng Leaf Peptide	CaCo-2	Colon Cancer	MTT assay	IC₅₀ = 104 ± 11.3 µM	48-h	Colon	None
6766	33462944	2021	FKEHGY	GP-1	6	Linear	L	None	Amidation	Free	Anticancer	Ginseng Leaf Peptide	CT-26	Colorectal Cancer	MTT assay	IC₅₀ = 86.4 ± 9.46 µM	48-h	Colon	None
6745	34935253	2021	WHLV	LCP-3	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	CaCo-2	Colon Cancer	MTT assay	IC₅₀ = 68.2 ± 7.11 μM	48-h	Colon	None
6743	34935253	2021	WHLV	LCP-3	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	MKN-45	Gastric Cancer	MTT assay	IC₅₀ = 86.9 ± 9.11 μM	48-h	Stomach	None
6744	34935253	2021	WHLV	LCP-3	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	HepG-2	Gastric Cancer	MTT assay	IC₅₀ = 85.2 ± 9.27 μM	48-h	Stomach	None
6740	34935253	2021	WAHT	LCP-2	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	HepG-2	Gastric Cancer	MTT assay	IC₅₀ = 96.9 ± 9.91 μM	48-h	Stomach	None
6741	34935253	2021	WAHT	LCP-2	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	CaCo-2	Colon Cancer	MTT assay	IC₅₀ = 100 ± 11.6 μM	48-h	Colon	None
6742	34935253	2021	WHLV	LCP-3	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	SGC-7901	Gastric Cancer	MTT assay	IC₅₀ = 101 ± 10.6 μM	48-h	Stomach	None
6738	34935253	2021	WAHT	LCP-2	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	SGC-7901	Gastric Cancer	MTT assay	IC₅₀ = 116 ± 12.4 μM	48-h	Stomach	None
6739	34935253	2021	WAHT	LCP-2	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	MKN-45	Gastric Cancer	MTT assay	IC₅₀ = 107 ± 11.8 μM	48-h	Stomach	None
6735	34935253	2021	FHVL	LCP-1	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	MKN-45	Gastric Cancer	MTT assay	IC₅₀ = 128 ± 13.5 μM	48-h	Stomach	None
6736	34935253	2021	FHVL	LCP-1	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	HepG-2	Gastric Cancer	MTT assay	IC₅₀ = 123 ± 12.9 μM	48-h	Stomach	None
6737	34935253	2021	FHVL	LCP-1	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	CaCo-2	Colon Cancer	MTT assay	IC₅₀ = 131 ± 13.4 μM	48-h	Colon	None
6733	33757145	2021	RALGWSCL	P2	8	Linear	L	None	Free	Free	Anticancer	Zingiber officinale	Raji	Lymphoma Cancer	MTT assay	IC₅₀ = 700 μg/mL	24-h	Blood	None
6734	34935253	2021	FHVL	LCP-1	4	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Laminaria japonica	SGC-7901	Gastric Cancer	MTT assay	IC₅₀ = 111 ± 10.6 μM	48-h	Stomach	None
6732	33757145	2021	RALGWSCL	P2	8	Linear	L	None	Free	Free	Anticancer	Zingiber officinale	MOLT-4	Luekemia Cancer	MTT assay	IC₅₀ = 700 μg/mL	24-h	Blood	None
6731	33757145	2021	RALGWSCL	P2	8	Linear	L	None	Free	Free	Anticancer	Zingiber officinale	NB-4	Luekemia Cancer	MTT assay	IC₅₀ = 600 μg/mL	24-h	Blood	None
6729	34394384	2021	SLSLSVAR	MIPP	8	Linear	L	None	Free	Free	Anticancer	Morchella importuna	HeLa	Cervical Cancer	MTT assay	Inhibitory rate = 59.36 ± 3.67% at 400 μg/mL	24-h	Cervix	None
6691	33489681	2021	ADLPGLK	Chickpea	7	Linear	L	None	Free	Free	Anticancer	Cicer arietinum L.	MCF-7	Breast Cancer	Sulforhodamine B assay	IC₅₀ = 110.3 ± 2.97µM	NA	Breast	None
6690	33489681	2021	ADLPGLK	Chickpea	7	Linear	L	None	Free	Free	Anticancer	Cicer arietinum L.	MDA-MB-231	Breast Cancer	Sulforhodamine B assay	IC₅₀ = 107.2 ± 1.62µM	NA	Breast	None
6688	33489681	2021	ADLPGLK	Chickpea	7	Linear	L	None	Free	Free	Anticancer	Cicer arietinum L.	A-549	Lung Cancer	Sulforhodamine B assay	IC₅₀ = 126.4 ± 1.98 µM	NA	Lung	None
6689	33489681	2021	ADLPGLK	Chickpea	7	Linear	L	None	Free	Free	Anticancer	Cicer arietinum L.	HepG-2	Liver Cancer	Sulforhodamine B assay	IC₅₀ = 113.7 ± 0.99 µM	NA	Liver	None
6687	33489681	2021	ADLPGLK	Chickpea	7	Linear	L	None	Free	Free	Anticancer	Cicer arietinum L.	Ishikawa	Endometrial Cancer	Sulforhodamine B assay	IC₅₀ = 101.5 ± 1.83 µM	NA	Endometrium	None
6686	33489681	2021	ADLPGLK	Chickpea	7	Linear	L	None	Free	Free	Anticancer	Cicer arietinum L.	PA-1	Ovarian Cancer	Sulforhodamine B assay	IC₅₀ = 133.4 ± 0.70µM	NA	Ovary	None
6685	33595876	2021	VKLRSLLCS	VS-9	9	Linear	L	None	Free	Free	Anticancer	Allium sativum	K-562	Blood Cancer	MTT assay	IC₅₀ = 1.57 mM	48-h	Blood	None
6684	33595876	2021	VKLRSLLCS	VS-9	9	Linear	L	None	Free	Free	Anticancer	Allium sativum	MOLT-4	Blood Cancer	MTT assay	IC₅₀ = 0.84 mM	48-h	Blood	None
6635	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 5c	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.568 ± 1.139 μM	72-h	Liver	None
6634	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 5b	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 7.088 ± 0.784 μM	72-h	Liver	None
6632	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4c	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.631 ± 0.932 μM	72-h	Liver	None
6633	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 5a	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 7.117 ± 0.790 μM	72-h	Liver	None
6631	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4c	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 19.552 ± 1.032 μM	72-h	Breast	None
6630	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 7.166 ± 0.892 μM	72-h	Liver	None
6628	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4a	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 7.31 ± 0.595 μM	72-h	Liver	None
6629	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 9.188 ± 0.545 μM	72-h	Breast	None
6626	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3c	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 16.957 ± 1.161 μM	72-h	Liver	None
6627	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4a	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 9.304 ± 0.536 μM	72-h	Breast	None
6624	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3b	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.66 ± 0.792 μM	72-h	Liver	None
6625	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3c	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 22.864 ± 0.992 μM	72-h	Breast	None
6623	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3b	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 9.911 ± 0.491 μM	72-h	Breast	None
6620	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 2c	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 19.318 ± 1.057 μM	72-h	Liver	None
6621	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3a	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 10.316 ± 0.546 μM	72-h	Breast	None
6622	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3a	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 8.063 ± 0.863 μM	72-h	Liver	None
6617	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 2b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 20.697 ± 0.974 μM	72-h	Breast	None
6618	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 2b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 18.681 ± 0.988 μM	72-h	Liver	None
6619	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 2c	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 24.943 ± 1.082 μM	72-h	Breast	None
6615	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1c	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 17.011 ± 0.965 μM	72-h	Liver	None
6616	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 2a	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 17.513 ± 0.876 μM	72-h	Liver	None
6614	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1c	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 34.894 ± 1.273 μM	72-h	Breast	None
6612	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 10.904 ± 0.534 μM	72-h	Breast	None
6613	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 8.724 ± 0.474 μM	72-h	Liver	None
6610	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1a	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 15.329 ± 0.672 μM	72-h	Breast	None
6611	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1a	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 6.615 ± 0.353 μM	72-h	Liver	None
6608	32806659	2020	WP	cyclic dipeptide - 7b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 97.1 µM	72-h	Lung	None
6609	32806659	2020	WP	cyclic dipeptide - 7b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 82.5 µM	72-h	Breast	None
6606	32806659	2020	WP	cyclic dipeptide - 7b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 92.2 µM	72-h	Cervix	None
6607	32806659	2020	WP	cyclic dipeptide - 7b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 82.3 µM	72-h	Liver	None
6603	32806659	2020	WW	cyclic dipeptide - 6b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 92.8 µM	72-h	Liver	None
6604	32806659	2020	WW	cyclic dipeptide - 6b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 99.3 µM	72-h	Lung	None
6605	32806659	2020	WW	cyclic dipeptide - 6b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 39.9 µM	72-h	Breast	None
6600	32806659	2020	WY	cyclic dipeptide - 5b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 98.0 µM	72-h	Lung	None
6601	32806659	2020	WY	cyclic dipeptide - 5b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 42.8 µM	72-h	Breast	None
6602	32806659	2020	WW	cyclic dipeptide - 6b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 91.4 µM	72-h	Cervix	None
6598	32806659	2020	WY	cyclic dipeptide - 5b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 94.8 µM	72-h	Cervix	None
6599	32806659	2020	WY	cyclic dipeptide - 5b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 97.5 µM	72-h	Liver	None
6596	32806659	2020	WF	cyclic dipeptide - 4b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 61.5 µM	72-h	Lung	None
6597	32806659	2020	WF	cyclic dipeptide - 4b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 32.3 µM	72-h	Breast	None
6593	32806659	2020	WF	cyclic dipeptide - 4a	2	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 100 µM	72-h	Breast	None
6594	32806659	2020	WF	cyclic dipeptide - 4b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 75.8 µM	72-h	Cervix	None
6595	32806659	2020	WF	cyclic dipeptide - 4b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 80.3 µM	72-h	Liver	None
6590	32806659	2020	WL	cyclic dipeptide - 3b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 41.4 µM	72-h	Breast	None
6591	32806659	2020	WF	cyclic dipeptide - 4a	2	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 100 µM	72-h	Cervix	None
6592	32806659	2020	WF	cyclic dipeptide - 4a	2	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 100 µM	72-h	Lung	None
6586	32806659	2020	WG	cyclic dipeptide - 1b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 33.7 µM	72-h	Breast	None
6587	32806659	2020	WA	cyclic dipeptide - 2b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 93.1 µM	72-h	Cervix	None
6588	32806659	2020	WA	cyclic dipeptide - 2b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 45.6 µM	72-h	Breast	None
6589	32806659	2020	WL	cyclic dipeptide - 3b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 85.2 µM	72-h	Cervix	None
6583	32806659	2020	WG	cyclic dipeptide - 1b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 95.3 µM	72-h	Cervix	None
6584	32806659	2020	WG	cyclic dipeptide - 1b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 87.7 µM	72-h	Liver	None
6585	32806659	2020	WG	cyclic dipeptide - 1b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 72.4 µM	72-h	Lung	None
6404	31747558	2020	FSPAG	Longicalycinin A cyclic analogue 18	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colon Cancer	MTT assay	22.8% Cell death at 100 µg/ml	24-h	Colon	None
6403	31747558	2020	FSPAG	Longicalycinin A cyclic analogue 18	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	46.58% Cell death at 100 µg/ml	24-h	Liver	None
6402	31747558	2020	FSPAG	Longicalycinin A cyclic analogue 18	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.06 ± 0.0014 µg/ml	24-h	Colon	None
6400	31747558	2020	FSPAG	Longicalycinin A linear analogue 18	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	56.51% Cell death at 100 µg/ml	24-h	Colon	None
6401	31747558	2020	FSPAG	Longicalycinin A cyclic analogue 18	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.68 ± 0.0014 µg/ml	24-h	Liver	None
6399	31747558	2020	FSPAG	Longicalycinin A linear analogue 18	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	15.55% Cell death at 100 µg/ml	24-h	Liver	None
6397	31747558	2020	FSPAG	Longicalycinin A linear analogue 18	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.33 ± 0.0007 µg/ml	24-h	Liver	None
6398	31747558	2020	FSPAG	Longicalycinin A linear analogue 18	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.2 ± 0.0014 µg/ml	24-h	Colon	None
6395	31747558	2020	FSPFA	Longicalycinin A cyclic analogue 17	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	74.53% Cell death at 100 µg/ml	24-h	Liver	None
6396	31747558	2020	FSPFA	Longicalycinin A cyclic analogue 17	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	76.14% Cell death at 100 µg/ml	24-h	Colon	None
6394	31747558	2020	FSPFA	Longicalycinin A cyclic analogue 17	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.2 ± 0.0007 µg/ml	24-h	Colon	None
6393	31747558	2020	FSPFA	Longicalycinin A cyclic analogue 17	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.4 ± 0.0014 µg/ml	24-h	Liver	None
6391	31747558	2020	FSPFA	Longicalycinin A linear analogue 17	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	27.54% Cell death at 100 µg/ml	24-h	Liver	None
6392	31747558	2020	FSPFA	Longicalycinin A linear analogue 17	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	75.68% Cell death at 100 µg/ml	24-h	Colon	None
6390	31747558	2020	FSPFA	Longicalycinin A linear analogue 17	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.33 ± 0.0035 µg/ml	24-h	Colon	None
6389	31747558	2020	FSPFA	Longicalycinin A linear analogue 17	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.33 ± 0.0007 µg/ml	24-h	Liver	None
6387	31747558	2020	FTPFV	Longicalycinin A cyclic analogue 16	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	42.33% Cell death at 100 µg/ml	24-h	Liver	None
6388	31747558	2020	FTPFV	Longicalycinin A cyclic analogue 16	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	29.87% Cell death at 100 µg/ml	24-h	Colon	None
6386	31747558	2020	FTPFV	Longicalycinin A cyclic analogue 16	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.4 ± 0.0028 µg/ml	24-h	Colon	None
6384	31747558	2020	FTPFV	Longicalycinin A linear analogue 16	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	88.24% Cell death at 100 µg/ml	24-h	Colon	None
6385	31747558	2020	FTPFV	Longicalycinin A cyclic analogue 16	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 12.1 ± 0.0007 µg/ml	24-h	Liver	None
6383	31747558	2020	FTPFV	Longicalycinin A linear analogue 16	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	15.76% Cell death at 100 µg/ml	24-h	Liver	None
6382	31747558	2020	FTPFV	Longicalycinin A linear analogue 16	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.11 ± 0.0056 µg/ml	24-h	Colon	None
6381	31747558	2020	FTPFV	Longicalycinin A linear analogue 16	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 11.1 ± 0.0007 µg/ml	24-h	Liver	None
6379	31747558	2020	PYGFV	Longicalycinin A cyclic analogue 15	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	52.33% Cell death at 100 µg/ml	24-h	Liver	None
6380	31747558	2020	PYGFV	Longicalycinin A cyclic analogue 15	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	27.43% Cell death at 100 µg/ml	24-h	Colon	None
6378	31747558	2020	PYGFV	Longicalycinin A cyclic analogue 15	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.23 ± 0.0007 µg/ml	24-h	Colon	None
6377	31747558	2020	PYGFV	Longicalycinin A cyclic analogue 15	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.33 ± 0 µg/ml	24-h	Liver	None
6375	31747558	2020	PYFFL	Longicalycinin A cyclic analogue 14	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	70.69% Cell death at 100 µg/ml	24-h	Liver	None
6376	31747558	2020	PYFFL	Longicalycinin A cyclic analogue 14	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	52.38% Cell death at 100 µg/ml	24-h	Colon	None
6374	31747558	2020	PYFFL	Longicalycinin A cyclic analogue 14	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.92 ± 0.0021 µg/ml	24-h	Colon	None
6373	31747558	2020	PYFFL	Longicalycinin A cyclic analogue 14	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.46 ± 0.0028 µg/ml	24-h	Liver	None
6372	31747558	2020	VTPFL	Longicalycinin A cyclic analogue 13	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	28.62% Cell death at 100 µg/ml	24-h	Colon	None
6371	31747558	2020	VTPFL	Longicalycinin A cyclic analogue 13	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	55.35% Cell death at 100 µg/ml	24-h	Liver	None
6370	31747558	2020	VTPFL	Longicalycinin A cyclic analogue 13	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.08 ± 0.0007 µg/ml	24-h	Colon	None
6369	31747558	2020	VTPFL	Longicalycinin A cyclic analogue 13	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.44 ± 0.0014 µg/ml	24-h	Liver	None
6368	31747558	2020	VTPFL	Longicalycinin A linear analogue 13	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	81.11% Cell death at 100 µg/ml	24-h	Colon	None
6367	31747558	2020	VTPFL	Longicalycinin A linear analogue 13	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	11.79% Cell death at 100 µg/ml	24-h	Liver	None
6366	31747558	2020	VTPFL	Longicalycinin A linear analogue 13	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 17.2 ± 0.0014 µg/ml	24-h	Colon	None
6365	31747558	2020	VTPFL	Longicalycinin A linear analogue 13	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.26 ± 0.0028 µg/ml	24-h	Liver	None
6364	31747558	2020	FYPFI	Longicalycinin A cyclic analogue 12	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	52.72% Cell death at 100 µg/ml	24-h	Colon	None
6363	31747558	2020	FYPFI	Longicalycinin A cyclic analogue 12	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	63.84% Cell death at 100 µg/ml	24-h	Liver	None
6361	31747558	2020	FYPFI	Longicalycinin A cyclic analogue 12	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 12.37 ± 0.0014 µg/ml	24-h	Liver	None
6362	31747558	2020	FYPFI	Longicalycinin A cyclic analogue 12	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 13.2 ± 0 µg/ml	24-h	Colon	None
6360	31747558	2020	FYPFI	Longicalycinin A linear analogue 12	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	81.34% Cell death at 100 µg/ml	24-h	Colon	None
6359	31747558	2020	FYPFI	Longicalycinin A linear analogue 12	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	12.06% Cell death at 100 µg/ml	24-h	Liver	None
6356	31747558	2020	TVPFA	Longicalycinin A cyclic analogue 11	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	74.89% Cell death at 100 µg/ml	24-h	Colon	None
6357	31747558	2020	FYPFI	Longicalycinin A linear analogue 12	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 11.32 ± 0.0014 µg/ml	24-h	Liver	None
6358	31747558	2020	FYPFI	Longicalycinin A linear analogue 12	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 14.2 ± 0.0014 µg/ml	24-h	Colon	None
6354	31747558	2020	TVPFA	Longicalycinin A cyclic analogue 11	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.61 ± 0.0007 µg/ml	24-h	Colon	None
6355	31747558	2020	TVPFA	Longicalycinin A cyclic analogue 11	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	72.06% Cell death at 100 µg/ml	24-h	Liver	None
6353	31747558	2020	TVPFA	Longicalycinin A cyclic analogue 11	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.36 ± 0 µg/ml	24-h	Liver	None
6352	31747558	2020	TVPFA	Longicalycinin A linear analogue 11	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	88.47% Cell death at 100 µg/ml	24-h	Colon	None
6350	31747558	2020	TVPFA	Longicalycinin A linear analogue 11	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.67 ± 0.0014 µg/ml	24-h	Colon	None
6351	31747558	2020	TVPFA	Longicalycinin A linear analogue 11	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	70.28% Cell death at 100 µg/ml	24-h	Liver	None
6349	31747558	2020	TVPFA	Longicalycinin A linear analogue 11	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.56 ± 0.0021 µg/ml	24-h	Liver	None
6347	31747558	2020	FYPFA	Longicalycinin A cyclic analogue 10	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	72.06% Cell death at 100 µg/ml	24-h	Liver	None
6348	31747558	2020	FYPFA	Longicalycinin A cyclic analogue 10	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	71.27% Cell death at 100 µg/ml	24-h	Colon	None
6346	31747558	2020	FYPFA	Longicalycinin A cyclic analogue 10	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.56 ± 0.0028 µg/ml	24-h	Colon	None
6344	31747558	2020	FYPFA	Longicalycinin A linear analogue 10	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	92.09% Cell death at 100 µg/ml	24-h	Colon	None
6345	31747558	2020	FYPFA	Longicalycinin A cyclic analogue 10	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.28 ± 0 µg/ml	24-h	Liver	None
6343	31747558	2020	FYPFA	Longicalycinin A linear analogue 10	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	76.72% Cell death at 100 µg/ml	24-h	Liver	None
6341	31747558	2020	FYPFA	Longicalycinin A linear analogue 10	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.5 ± 0.0014 µg/ml	24-h	Liver	None
6342	31747558	2020	FYPFA	Longicalycinin A linear analogue 10	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.5 ± 0.0007 µg/ml	24-h	Colon	None
6340	31747558	2020	FYPFV	Longicalycinin A cyclic analogue 9	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	76.25% Cell death at 100 µg/ml	24-h	Colon	None
6338	31747558	2020	FYPFV	Longicalycinin A cyclic analogue 9	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.7 ± 0.0056 µg/ml	24-h	Colon	None
6339	31747558	2020	FYPFV	Longicalycinin A cyclic analogue 9	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	73.98% Cell death at 100 µg/ml	24-h	Liver	None
6337	31747558	2020	FYPFV	Longicalycinin A cyclic analogue 9	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.67 ± 0 µg/ml	24-h	Liver	None
6334	31747558	2020	FYPFV	Longicalycinin A linear analogue 9	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.44 ± 0.5536 µg/ml	24-h	Colon	None
6335	31747558	2020	FYPFV	Longicalycinin A linear analogue 9	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	72.74% Cell death at 100 µg/ml	24-h	Liver	None
6336	31747558	2020	FYPFV	Longicalycinin A linear analogue 9	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	1.59% Cell death at 100 µg/ml	24-h	Colon	None
6331	31747558	2020	FYPVG	Longicalycinin A cyclic analogue 8	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	36.85% Cell death at 100 µg/ml	24-h	Liver	None
6332	31747558	2020	FYPVG	Longicalycinin A cyclic analogue 8	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	29.87% Cell death at 100 µg/ml	24-h	Colon	None
6333	31747558	2020	FYPFV	Longicalycinin A linear analogue 9	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.33 ± 0.0007 µg/ml	24-h	Liver	None
6329	31747558	2020	FYPVG	Longicalycinin A cyclic analogue 8	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.12 ± 0.0007 µg/ml	24-h	Liver	None
6330	31747558	2020	FYPVG	Longicalycinin A cyclic analogue 8	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.67 ± 0.0028 µg/ml	24-h	Colon	None
6327	31747558	2020	FYPVG	Longicalycinin A linear analogue 8	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	15.35% Cell death at 100 µg/ml	24-h	Liver	None
6328	31747558	2020	FYPVG	Longicalycinin A linear analogue 8	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	88.01% Cell death at 100 µg/ml	24-h	Colon	None
6325	31747558	2020	FYPVG	Longicalycinin A linear analogue 8	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.35 ± 0.0014 µg/ml	24-h	Liver	None
6326	31747558	2020	FYPVG	Longicalycinin A linear analogue 8	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.88 ± 0.0014 µg/ml	24-h	Colon	None
6324	31747558	2020	PYVFA	Longicalycinin A cyclic analogue 7	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	22.86% Cell death at 100 µg/ml	24-h	Colon	None
6322	31747558	2020	PYVFA	Longicalycinin A cyclic analogue 7	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.11 ± 0.0035 µg/ml	24-h	Colon	None
6323	31747558	2020	PYVFA	Longicalycinin A cyclic analogue 7	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	47.68% Cell death at 100 µg/ml	24-h	Liver	None
6321	31747558	2020	PYVFA	Longicalycinin A cyclic analogue 7	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.21 ± 0.0056 µg/ml	24-h	Liver	None
6319	31747558	2020	PYVFA	Longicalycinin A linear analogue 7	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	82.33% Cell death at 100 µg/ml	24-h	Liver	None
6320	31747558	2020	PYVFA	Longicalycinin A linear analogue 7	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	84.17% Cell death at 100 µg/ml	24-h	Colon	None
6317	31747558	2020	PYVFA	Longicalycinin A linear analogue 7	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.6 ± 0.0007 µg/ml	24-h	Liver	None
6318	31747558	2020	PYVFA	Longicalycinin A linear analogue 7	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.78 ± 0.0212 µg/ml	24-h	Colon	None
6316	31747558	2020	VYPIA	Longicalycinin A cyclic analogue 6	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	27.61% Cell death at 100 µg/ml	24-h	Colon	None
6314	31747558	2020	VYPIA	Longicalycinin A cyclic analogue 6	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.2 ± 0.0021 µg/ml	24-h	Colon	None
6315	31747558	2020	VYPIA	Longicalycinin A cyclic analogue 6	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	51.79% Cell death at 100 µg/ml	24-h	Liver	None
6313	31747558	2020	VYPIA	Longicalycinin A cyclic analogue 6	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 17.34 ± 0.0014 µg/ml	24-h	Liver	None
6311	31747558	2020	VYPIA	Longicalycinin A linear analogue 6	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	38.64% Cell death at 100 µg/ml	24-h	Liver	None
6312	31747558	2020	VYPIA	Longicalycinin A linear analogue 6	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	49.33% Cell death at 100 µg/ml	24-h	Colon	None
6309	31747558	2020	VYPIA	Longicalycinin A linear analogue 6	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.98 ± 0.0014 µg/ml	24-h	Liver	None
6310	31747558	2020	VYPIA	Longicalycinin A linear analogue 6	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.31 ± 0.0063 µg/ml	24-h	Colon	None
6308	31747558	2020	FSPFG	Longicalycinin A cyclic analogue 5	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	97.74% Cell death at 100 µg/ml	24-h	Colon	None
6307	31747558	2020	FSPFG	Longicalycinin A cyclic analogue 5	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	41.37% Cell death at 100 µg/ml	24-h	Liver	None
6305	31747558	2020	FSPFG	Longicalycinin A cyclic analogue 5	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.45 ± 0.0056 µg/ml	24-h	Liver	None
6306	31747558	2020	FSPFG	Longicalycinin A cyclic analogue 5	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.98 ± 0.4256 µg/ml	24-h	Colon	None
6304	31747558	2020	FSPFG	Longicalycinin A linear analogue 5	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	91.52% Cell death at 100 µg/ml	24-h	Colon	None
6302	31747558	2020	FSPFG	Longicalycinin A linear analogue 5	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.97 ± 0.0049 µg/ml	24-h	Colon	None
6303	31747558	2020	FSPFG	Longicalycinin A linear analogue 5	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	76.72% Cell death at 100 µg/ml	24-h	Liver	None
6301	31747558	2020	FSPFG	Longicalycinin A linear analogue 5	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 8.99 ± 0.0014 µg/ml	24-h	Liver	None
6299	31747558	2020	AYPFG	Longicalycinin A cyclic analogue 4	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	71.1% Cell death at 100 µg/ml	24-h	Liver	None
6300	31747558	2020	AYPFG	Longicalycinin A cyclic analogue 4	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	52.49% Cell death at 100 µg/ml	24-h	Colon	None
6298	31747558	2020	AYPFG	Longicalycinin A cyclic analogue 4	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.33 ± 0.0035 µg/ml	24-h	Colon	None
6297	31747558	2020	AYPFG	Longicalycinin A cyclic analogue 4	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.77 ± 0.007 µg/ml	24-h	Liver	None
6295	31747558	2020	AYPFG	Longicalycinin A linear analogue 4	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	27.13% Cell death at 100 µg/ml	24-h	Liver	None
6296	31747558	2020	AYPFG	Longicalycinin A linear analogue 4	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	75.91% Cell death at 100 µg/ml	24-h	Colon	None
6294	31747558	2020	AYPFG	Longicalycinin A linear analogue 4	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.78 ± 0.0021 µg/ml	24-h	Colon	None
6293	31747558	2020	AYPFG	Longicalycinin A linear analogue 4	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.53 ± 0.0014 µg/ml	24-h	Liver	None
6291	31747558	2020	GYPFA	Longicalycinin A cyclic analogue 3	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	56.72% Cell death at 100 µg/ml	24-h	Liver	None
6292	31747558	2020	GYPFA	Longicalycinin A cyclic analogue 3	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	28.51% Cell death at 100 µg/ml	24-h	Colon	None
6290	31747558	2020	GYPFA	Longicalycinin A cyclic analogue 3	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.28 ± 0.0063 µg/ml	24-h	Colon	None
6288	31747558	2020	GYPFA	Longicalycinin A linear analogue 3	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	87.56% Cell death at 100 µg/ml	24-h	Colon	None
6289	31747558	2020	GYPFA	Longicalycinin A cyclic analogue 3	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.5 ± 0.0056 µg/ml	24-h	Liver	None
6287	31747558	2020	GYPFA	Longicalycinin A linear analogue 3	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	82.33% Cell death at 100 µg/ml	24-h	Liver	None
6286	31747558	2020	GYPFA	Longicalycinin A linear analogue 3	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.4 ± 0 µg/ml	24-h	Colon	None
6285	31747558	2020	GYPFA	Longicalycinin A linear analogue 3	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.77 ± 0.0007 µg/ml	24-h	Liver	None
6284	31747558	2020	PYFFL	Longicalycinin A linear analogue 14	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	82.36% Cell death at 100 µg/ml	24-h	Colon	None
6283	31747558	2020	PYFFL	Longicalycinin A linear analogue 14	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	13.02% Cell death at 100 µg/ml	24-h	Liver	None
6282	31747558	2020	PYFFL	Longicalycinin A linear analogue 14	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.12 ± 0.0042 µg/ml	24-h	Colon	None
6280	31747558	2020	FYPFG	Longicalycinin A (Linear)	5	Linear	L	None	Free	Free	Anticancer	Synthetic	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.61 ± 0.0007 µg/ml	24-h	Colon	None
6281	31747558	2020	PYFFL	Longicalycinin A linear analogue 14	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.67 ± 0.0007 µg/ml	24-h	Liver	None
6279	31747558	2020	FYPFG	Longicalycinin A (Linear)	5	Linear	L	None	Free	Free	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.18 ± 0.0014 µg/ml	24-h	Liver	None
6277	31747558	2020	FYPFG	Longicalycinin A	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.45 ± 0.0042 µg/ml	24-h	Liver	None
6278	31747558	2020	FYPFG	Longicalycinin A	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.87 ± 0.0021 µg/ml	24-h	Colon	None
6276	31747558	2020	FYPFG	Longicalycinin A	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Dianthus superbus	EAC cell Line	Breast Cancer	MTT assay	CTC₅₀ = 6.17 µM	24-h	Breast	None
6274	31747558	2020	FYPFG	Longicalycinin A	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Dianthus superbus	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 13.52 µg/ml	24-h	Liver	None
6275	31747558	2020	FYPFG	Longicalycinin A	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Dianthus superbus	DLA cell line	Lung Cancer	MTT assay	CTC₅₀ = 2.62 µM	24-h	Thymus	None
6272	31747558	2020	GYPFV	Longicalycinin A Cyclic analogue 1	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	69.73% Cell death at 100 µg/ml	24-h	Liver	None
6273	31747558	2020	GYPFV	Longicalycinin A Cyclic analogue 1	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	71.5% Cell death at 100 µg/ml	24-h	Colon	None
6271	31747558	2020	GYPFV	Longicalycinin A Cyclic analogue 1	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.4 ± 0.0028 µg/ml	24-h	Colon	None
6269	31747558	2020	LYPFA	Longicalycinin A linear analogue 2	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	88.47% Cell death at 100 µg/ml	24-h	Colon	None
6270	31747558	2020	GYPFV	Longicalycinin A Cyclic analogue 1	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.2 ± 0.007 µg/ml	24-h	Liver	None
6267	31747558	2020	LYPFA	Longicalycinin A linear analogue 2	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.33 ± 0 µg/ml	24-h	Colon	None
6268	31747558	2020	LYPFA	Longicalycinin A linear analogue 2	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	71.37% Cell death at 100 µg/ml	24-h	Liver	None
6266	31747558	2020	LYPFA	Longicalycinin A linear analogue 2	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 8.76 ± 0.0035 µg/ml	24-h	Liver	None
6265	31747558	2020	GYPFV	Longicalycinin A linear analogue 1	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	83.02% Cell death at 100 µg/ml	24-h	Colon	None
6263	31747558	2020	GYPFV	Longicalycinin A linear analogue 1	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.45 ± 0.0042 µg/ml	24-h	Colon	None
6264	31747558	2020	GYPFV	Longicalycinin A linear analogue 1	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	13.29% Cell death at 100 µg/ml	24-h	Liver	None
6262	31747558	2020	GYPFV	Longicalycinin A linear analogue 1	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.66 ± 0.0007 µg/ml	24-h	Liver	None
6246	32641940	2019	GEGSGA	C2Triazole	6	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	81.22 ± 0.30 inhibition % at 10 µM	48-h	Breast	None
6247	32641940	2019	GEGSGA	C2Triazole	6	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	HT-29	Colon Cancer	MTT assay	92.56 ± 0.28 inhibition % at 10 µM	48-h	Colon	None
6244	32641940	2019	GLTSK	C1Triazole	5	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	HT-29	Colon Cancer	MTT assay	92.8 ± 0.16 inhibition % at 10 µM	48-h	Colon	None
6245	32641940	2019	GEGSGA	C2Triazole	6	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	82.12 ± 0.48 inhibition % at 10 µM	48-h	Breast	None
6242	32641940	2019	GLTSK	C1Triazole	5	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	59.76 ± 10.34 inhibition % at 10 µM	48-h	Breast	None
6243	32641940	2019	GLTSK	C1Triazole	5	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	79.9 ± 0.49 inhibition % at 10 µM	48-h	Breast	None
6240	32641940	2019	GEGSGA	C2 mother	6	Linear	L	None	Free	Free	Anticancer	Common bean fractions	MDA-MB-231	Breast Cancer	MTT assay	79.32 ± 0.23 inhibition % at 10 µM	48-h	Breast	None
6241	32641940	2019	GEGSGA	C2 mother	6	Linear	L	None	Free	Free	Anticancer	Common bean fractions	HT-29	Colon Cancer	MTT assay	92.79 ± 0.54 inhibition % at 10 µM	48-h	Colon	None
6239	32641940	2019	GEGSGA	C2 mother	6	Linear	L	None	Free	Free	Anticancer	Common bean fractions	MCF-7	Breast Cancer	MTT assay	83.39 ± 0.84 inhibition % at 10 µM	48-h	Breast	None
6237	32641940	2019	GLTSK	C1 mother	5	Linear	L	None	Free	Free	Anticancer	Common bean fractions	MDA-MB-231	Breast Cancer	MTT assay	78.7 ± 1.60 inhibition % at 10 µM	48-h	Breast	None
6238	32641940	2019	GLTSK	C1 mother	5	Linear	L	None	Free	Free	Anticancer	Common bean fractions	HT-29	Colon Cancer	MTT assay	93.01 ± 1.01 inhibition % at 10 µM	48-h	Colon	None
6236	32641940	2019	GLTSK	C1 mother	5	Linear	L	None	Free	Free	Anticancer	Common bean fractions	MCF-7	Breast Cancer	MTT assay	50.11 ± 2.09 inhibition % at 10 µM	48-h	Breast	None
6219	30614230	2019	RDTQ	oligopeptide 3	4	Linear	L	None	Free	Free	Anticancer	Sarcophyton glaucum	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 5.6 mmol/L	26 h	Cervix	None
6218	30614230	2019	AERQ	oligopeptide 2	4	Linear	L	None	Free	Free	Anticancer	Sarcophyton glaucum	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 4.9 mmol/L	25 h	Cervix	None
6217	30614230	2019	AGAPGG	oligopeptide 1	6	Linear	L	None	Free	Free	Anticancer	Sarcophyton glaucum	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 8.6 mmol/L	24 h	Cervix	None
6191	31683101	2019	(Beta-A)H	Carnosine	2	Linear	L	None	Free	Free	Anti-inflammatory and Antitumor	Muscular and Nervous tissues of vertebrates	MGH-U1 (EJ)	Bladder Cancer	MTT assay	IC₅₀ = 50 mM	24-h	Bladder	None
6013	30241374	2018	Structure in scheme 2	Compound 6b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 11.53 ± 1.70 µM	Not Available	Liver	None
6014	30241374	2018	Structure in scheme 2	Compound 6c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 12.07 ± 1.68 µM	Not Available	Liver	None
6011	30241374	2018	Structure in scheme 2	Compound 6a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 12.44 ± 1.3 µM	Not Available	Liver	None
6012	30241374	2018	Structure in scheme 2	Compound 6b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 10.87 ± 1.10 µM	Not Available	Breast	None
6009	30241374	2018	Structure in scheme 2	Compound 5c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 7.53 ± 1.33 µM	Not Available	Liver	None
6010	30241374	2018	Structure in scheme 2	Compound 6a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 11.83 ± 1.62 µM	Not Available	Breast	None
6007	30241374	2018	Structure in scheme 2	Compound 5b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 10.09 ± 2.05 µM	Not Available	Liver	None
6008	30241374	2018	Structure in scheme 2	Compound 5c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 9.41 ± 1.25 µM	Not Available	Breast	None
6005	30241374	2018	Structure in scheme 2	Compound 5a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 11.19 ± 1.95 µM	Not Available	Liver	None
6006	30241374	2018	Structure in scheme 2	Compound 5b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 11.32 ± 1.15 µM	Not Available	Breast	None
6003	30241374	2018	Structure in scheme 2	Compound 4c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 18.84 ± 1.47 µM	Not Available	Liver	None
6004	30241374	2018	Structure in scheme 2	Compound 5a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 12.67 ± 2.40 µM	Not Available	Breast	None
6001	30241374	2018	Structure in scheme 2	Compound 4b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 10.25 ± 2.20 µM	Not Available	Liver	None
6002	30241374	2018	Structure in scheme 2	Compound 4c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 29.15 ± 1.39 µM	Not Available	Breast	None
6000	30241374	2018	Structure in scheme 2	Compound 4b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 10.45 ± 1.33 µM	Not Available	Breast	None
5998	30241374	2018	Structure in scheme 2	Compound 3c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 26.64 ± 1.85 µM	Not Available	Liver	None
5999	30241374	2018	Structure in scheme 2	Compound 4a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 11.59 ± 2.70 µM	Not Available	Liver	None
5997	30241374	2018	Structure in scheme 2	Compound 3c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 29.55 ± 2.06 µM	Not Available	Breast	None
5994	30241374	2018	Structure in scheme 2	Compound 3a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 26.01 ± 2.35 µM	Not Available	Liver	None
5995	30241374	2018	Structure in scheme 2	Compound 3b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 25.33 ± 1.18 µM	Not Available	Breast	None
5996	30241374	2018	Structure in scheme 2	Compound 3b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 13.54 ± 1.45 µM	Not Available	Liver	None
5992	30241374	2018	Structure in scheme 1	Compound 2b	5	Cyclic	L	Structure in scheme 1	Structure in scheme 1	Structure in scheme 1	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 15.80 ± 1.66 µM	Not Available	Liver	None
5993	30241374	2018	Structure in scheme 1	Compound 2c	5	Cyclic	L	Structure in scheme 1	Structure in scheme 1	Structure in scheme 1	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 35.52 ± 1.83 µM	Not Available	Liver	None
5990	30241374	2018	Structure in scheme 1	Compound 2a	5	Cyclic	L	Structure in scheme 1	Structure in scheme 1	Structure in scheme 1	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 20.37 ± 1.36 µM	Not Available	Liver	None
5991	30241374	2018	Structure in scheme 1	Compound 2b	5	Cyclic	L	Structure in scheme 1	Structure in scheme 1	Structure in scheme 1	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 32.58 ± 1.50 µM	Not Available	Breast	None
5989	30241374	2018	Structure in scheme 1	Compound 2a	5	Cyclic	L	Structure in scheme 1	Structure in scheme 1	Structure in scheme 1	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 31.64 ± 1.30 µM	Not Available	Breast	None
5988	30373232	2018	(3-MeP)-(AHMOD)-A-Aib-IV-beta-A-N-(2-Hydroxyethyl)-1,2-propanediamine	Emericellipsin A	9	Linear	L	3-me-P = (3R)-3-methylproline; AHMOD = (2S,4S)-2-Amino-4-methyl-6-hydroxy-8-oxodecanoic acid; Aib = 2-Aminoisobutyric acid; β-alanine; N-(2-Hydroxyethyl)-1,2-propanediamine	N-(2-Hydroxyethyl)-1,2-propanediamine	2-methyldecanoic acid (2MDA)	Antimicrobial and Antitumor	Emericellopsis alkalina	HeLa	Cervical Cancer	MTT assay	EC₅₀ < 0.5 uM	24-h	Cervix	None
5987	30373232	2018	(3-MeP)-(AHMOD)-A-Aib-IV-beta-A-N-(2-Hydroxyethyl)-1,2-propanediamine	Emericellipsin A	9	Linear	L	3-me-P = (3R)-3-methylproline; AHMOD = (2S,4S)-2-Amino-4-methyl-6-hydroxy-8-oxodecanoic acid; Aib = 2-Aminoisobutyric acid; β-alanine; N-(2-Hydroxyethyl)-1,2-propanediamine	N-(2-Hydroxyethyl)-1,2-propanediamine	2-methyldecanoic acid (2MDA)	Antimicrobial and Antitumor	Emericellopsis alkalina	HepG-2	Liver Cancer	MTT assay	EC₅₀ = 2.8 uM	24-h	Liver	None
5962	None	2018	PIPRPIF	P18-2	7	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Analogue of Phakellistatin 18	BEL-7042	Cervical Cancer	Cytotoxicity assay	IC₅₀ >100 µM	Not Available	Cervix	None
5961	None	2018	PIPRPIF	P18-2	7	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Analogue of Phakellistatin 18	A-549	Lung Cancer	Cytotoxicity assay	IC₅₀ = 79.71 µM	Not Available	Lung	None
5959	None	2018	PIPYPIF	P18-1	7	Cyclic	L	Substitution of hydroxyl group at Tyrosine with sulfonyl fluoride	Cyclized	Cyclized	Anticancer	Analogue of Phakellistatin 18	A-549	Lung Cancer	Cytotoxicity assay	IC₅₀ = 67.53 µM	Not Available	Lung	None
5960	None	2018	PIPYPIF	P18-1	7	Cyclic	L	Substitution of hydroxyl group at Tyrosine with sulfonyl fluoride	Cyclized	Cyclized	Anticancer	Analogue of Phakellistatin 18	BEL-7042	Cervical Cancer	Cytotoxicity assay	IC₅₀ = 41.28 µM	Not Available	Cervix	None
5958	None	2018	PIPYPIF	Phakellistatin 18	7	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Marine Sponge Phakellia fusca	BEL-7042	Cervical Cancer	Cytotoxicity assay	IC₅₀ = 82.25 µM	Not Available	Cervix	None
5957	None	2018	PIPYPIF	Phakellistatin 18	7	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Marine Sponge Phakellia fusca	A-549	Lung Cancer	Cytotoxicity assay	IC₅₀ = 72.42 µM	Not Available	Lung	None
5949	29649141	2018	YVPGP	AAP-H	5	Linear	L	None	Free	Free	Anticancer	Anthopleura anjunae	DU-145	Prostate Cancer	MTT assay	IC₅₀ = 2.298 mM	72-h	Prostate	None
5817	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	PC-3/A24	Prostate Cancer	CCK-8 assay	EC₅₀ = 50.69 ± 1.58 μM	12-h	Prostate	None
5815	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	HT-29	Colon Cancer	CCK-8 assay	EC₅₀ = 96.00 ± 9.06 μM	12-h	Colon	None
5816	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	SW-620	Colorectal Cancer	CCK-8 assay	EC₅₀ = 102.35 ± 4.66 μM	12-h	Colon	None
5814	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	Colo-320	Colon Cancer	CCK-8 assay	EC₅₀ = 83.10 ± 1.41 μM	12-h	Colon	None
5812	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	A-549	Lung Cancer	CCK-8 assay	EC₅₀ = 119.84 ± 16.01 μM	12-h	Lung	None
5813	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	HepG-2	Liver Cancer	CCK-8 assay	EC₅₀ = 107.34 ± 11.87 μM	12-h	Liver	None
5798	28872704	2017	PD	Peptide 7b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 19.1 ± 0.04 µM	48-h	Breast	None
5800	28872704	2017	PD	Peptide 7b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 21.8 ± 0.03 µM	48-h	Lung	None
5801	28872704	2017	PD	Peptide 7b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 17.9 ± 0.02 µM	48-h	Cervix	None
5794	28872704	2017	FD	Peptide 6b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 18.4 ± 0.12 µM	48-h	Breast	None
5795	28872704	2017	FD	Peptide 6b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 61.5 ± 023µM	48-h	Liver	None
5796	28872704	2017	FD	Peptide 6b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 18.6 ± 0.04 µM	48-h	Lung	None
5791	28872704	2017	FE	Peptide 5b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 18.7 ± 0.04 µM	48-h	Liver	None
5793	28872704	2017	FE	Peptide 5b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 20.6 ± 0.04 µM	48-h	Cervix	None
5788	28872704	2017	HD	Peptide 4b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 28.4 ± 0.02 µM	48-h	Lung	None
5789	28872704	2017	HD	Peptide 4b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 19.9 ± 0.02 µM	48-h	Cervix	None
5790	28872704	2017	FE	Peptide 5b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 19.7 ± 0.06 µM	48-h	Breast	None
5784	28872704	2017	YD	Peptide 3b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 5.8 ± 0.02 µM	48-h	Lung	None
5786	28872704	2017	HD	Peptide 4b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 62.2 ± 0.02 µM	48-h	Breast	None
5787	28872704	2017	HD	Peptide 4b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 63.2 ± 0.03 µM	48-h	Liver	None
5781	28872704	2017	PE	Peptide 2b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 17.7 ± 0.04 µM	48-h	Cervix	None
5783	28872704	2017	YD	Peptide 3b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 62.3 ± 0.02 µM	48-h	Liver	None
5778	28872704	2017	PE	Peptide 2b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 12.1 ± 0.23 µM	48-h	Breast	None
5779	28872704	2017	PE	Peptide 2b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 19.3 ± 0.02 µM	48-h	Liver	None
5780	28872704	2017	PE	Peptide 2b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 19.9 ± 0.03 µM	48-h	Lung	None
5773	28872704	2017	PD	Peptide 7a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 24.4 ± 0.03 µM	48-h	Cervix	None
5774	28872704	2017	WD	Peptide 1b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 5.7 ± 0.03 µM	48-h	Breast	None
5768	28872704	2017	WD	Peptide 6a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 61.6 ± 0.18 µM	48-h	Lung	None
5771	28872704	2017	PD	Peptide 7a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 23.0 ± 0.05 µM	48-h	Liver	None
5772	28872704	2017	PD	Peptide 7a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 23.8 ± 0.03 µM	48-h	Lung	None
5764	28872704	2017	HD	Peptide 5a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 12.9 ± 0.23 µM	48-h	Lung	None
5766	28872704	2017	WD	Peptide 6a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 18.1 ± 0.01 µM	48-h	Breast	None
5767	28872704	2017	WD	Peptide 6a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 64.3 ± 0.01 µM	48-h	Liver	None
5756	28872704	2017	YD	Peptide 3a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 5.7 ± 0.04 µM	48-h	Lung	None
5758	28872704	2017	HE	Peptide 4a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 44.1 ± 0.02 µM	48-h	Breast	None
5752	28872704	2017	YE	Peptide 2a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 20.6 ± 0.03 µM	48-h	Lung	None
5754	28872704	2017	YD	Peptide 3a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 17.5 ± 0.04 µM	48-h	Breast	None
5755	28872704	2017	YD	Peptide 3a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 4.8 ± 0.12 µM	48-h	Liver	None
5750	28872704	2017	YE	Peptide 2a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 16.0 ± 0.13 µM	48-h	Breast	None
5751	28872704	2017	YE	Peptide 2a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 31.1 ± 0.03 µM	48-h	Liver	None
5747	28872704	2017	FE	Peptide 1a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 5.7 ± 0.04 µM	48-h	Liver	None
5748	28872704	2017	FE	Peptide 1a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 13.9 ± 0.03 µM	48-h	Lung	None
5749	28872704	2017	FE	Peptide 1a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 21.4 ± 0.02 µM	48-h	Cervix	None
5743	27218227	2017	HVLSRAPR	HR	8	Linear	L	None	Free	Free	Anticancer	Fraction identified from Tr1	A-549	Lung Cancer	MTT assay	15% inhibition at 500 μg/mL	48-h	Lung	None
5746	28872704	2017	FE	Peptide 1a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 64.4 ± 0.03 µM	48-h	Breast	None
5742	27218227	2017	HVLSRAPR	HR	8	Linear	L	None	Free	Free	Anticancer	Fraction identified from Tr1	SGC-7901	Gastric Cancer	MTT assay	20% inhibition at 500 μg/mL	48-h	Stomach	None
5740	27218227	2017	HVLSRAPR	HR	8	Linear	L	None	Free	Free	Anticancer	Fraction identified from Tr1	HT-29	Colon Cancer	MTT assay	IC₅₀ = 99.88 μg/mL	48-h	Colon	None
5741	27218227	2017	HVLSRAPR	HR	8	Linear	L	None	Free	Free	Anticancer	Fraction identified from Tr1	HepG-2	Liver Cancer	MTT assay	22% inhibition at 500 μg/mL	48-h	Liver	None
5469	26851022	2016	Beta-AH	L-Carnosine	2	Linear	L	beta-alanyl	Free	Free	Anti-inflammatory and Antitumor	Synthetic	A-2780	Ovarian Cancer	MTT assay	IC₅₀ = 165 mM	24-h	Ovary	None
5470	26851022	2016	Beta-AH	L-Carnosine	2	Linear	L	beta-alanyl	Free	Free	Anti-inflammatory and Antitumor	Synthetic	OVCAR-3	Ovarian Cancer	MTT assay	IC₅₀ = 125 mM	24-h	Ovary	None
5471	26851022	2016	Beta-AH	L-Carnosine	2	Linear	L	beta-alanyl	Free	Free	Anti-inflammatory and Antitumor	Synthetic	SK-OV-3	Ovarian Cancer	MTT assay	IC₅₀ = 485 mM	24-h	Ovary	None
5297	26952034	2016	DEDDD	XLAsp-P1	5	Linear	L	None	Free	Free	Antimicrobial	Xenopus laevis	Not Available	Breast Cancer	MTT assay	LC₅₀ < 5 μg/mL	24-h	Breast	None
5292	27129462	2016	RGSALTHLP	RP9	9	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Crocodylus siamensis	CaSki	Cervical Cancer	Sulforhodamine B assay	IC₅₀ = 168.33 ± 1.6 µM	24-h	Cervix	None
5291	27129462	2016	RGSALTHLP	RP9	9	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Crocodylus siamensis	HeLa	Cervical Cancer	Sulforhodamine B assay	IC₅₀ = 126.24 ± 3.5 µM	24-h	Cervix	None
5268	25854366	2015	FIGAIARLL	BmKn-24	9	Linear	L	None	Free	Free	Antimicrobial	Derivative of Bmkn-2	HSC-4	Tongue Squamous Cell Carcinoma	MTT assay	IC₅₀ between 29-97 µg/ml	24-h	Tongue	None
5224	27486068	2015	PcatPhexPhexPcat	Lipotetrapeptide-C16-PCatPCatPCatPCat-NH2	4	Linear	L	Pcat = L-4R-aminoproline ; Phex = L-4R-hexyloxyproline	Amidation	Palmitic acid	Anticancer	Synthetic	DU-145	Prostate Cancer	MTS assay	CC₅₀ = 16.5 µM	73-76h	Prostate	None
5225	27486068	2015	PcatPhexPhexPcat	Lipotetrapeptide-C16-PCatPCatPCatPCat-NH2	4	Linear	L	Pcat = L-4R-aminoproline ; Phex = L-4R-hexyloxyproline	Amidation	Palmitic acid	Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	MTS assay	CC₅₀ = 23 µM	73-76h	Pancreas	None
5221	27486068	2015	KKKK	C16-Lipotetrapeptide	4	Linear	L	None	Amidation	Palmitic acid	Anticancer	Synthetic	DU-145	Prostate Cancer	MTS assay	CC₅₀ = 18 µM	73-76h	Prostate	None
5222	27486068	2015	PcatPhexPhexPcat	Lipotetrapeptide-C16-PCatPCatPCatPCat-NH2	4	Linear	L	Pcat = L-4R-aminoproline ; Phex = L-4R-hexyloxyproline	Amidation	Palmitic acid	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTS assay	CC₅₀ = 12.5 µM	73-76h	Breast	None
5223	27486068	2015	PcatPhexPhexPcat	Lipotetrapeptide-C16-PCatPCatPCatPCat-NH2	4	Linear	L	Pcat = L-4R-aminoproline ; Phex = L-4R-hexyloxyproline	Amidation	Palmitic acid	Anticancer	Synthetic	JIMT-1	Breast Cancer	MTS assay	CC₅₀ = 17 µM	73-76h	Breast	None
5218	27486068	2015	KKK	C16-Liptotripeptide	3	Linear	L	None	Amidation	Palmitic acid	Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	MTS assay	CC₅₀ =16 µM	73-76h	Pancreas	None
5219	27486068	2015	KKKK	C16-Lipotetrapeptide	4	Linear	L	None	Amidation	Palmitic acid	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTS assay	CC₅₀ = 30 µM	73-76h	Breast	None
5220	27486068	2015	KKKK	C16-Lipotetrapeptide	4	Linear	L	None	Amidation	Palmitic acid	Anticancer	Synthetic	JIMT-1	Breast Cancer	MTS assay	CC₅₀ = 30 µM	73-76h	Breast	None
5215	27486068	2015	KKK	C14-Liptotripeptide	3	Linear	L	None	Amidation	Myristic acid	Anticancer	Synthetic	DU-145	Prostate Cancer	MTS assay	CC₅₀ =10 µM	73-76h	Prostate	None
5216	27486068	2015	KKK	C16-Liptotripeptide	3	Linear	L	None	Amidation	Palmitic acid	Anticancer	Synthetic	JIMT-1	Breast Cancer	MTS assay	CC₅₀ = 10 µM	73-76h	Breast	None
5217	27486068	2015	KKK	C16-Liptotripeptide	3	Linear	L	None	Amidation	Palmitic acid	Anticancer	Synthetic	DU-145	Prostate Cancer	MTS assay	CC₅₀ = 9 µM	73-76h	Prostate	None
5212	25633717	2015	Str given in figure	KEMTUB10	4	Linear	L	None	fluorine atom in para-position on the phenyl ring	N-tubuvaline fragment replaced with stable benzyl group	Anti-cancer	Synthetic analogue of natural tubulysins	MDA-MB-453	Breast Cancer	MTT assay	IC₅₀ = 16.3 ± 5.6 pM	72-h	Breast	None
5213	25633717	2015	Str given in figure	KEMTUB10	4	Linear	L	None	fluorine atom in para-position on the phenyl ring	N-tubuvaline fragment replaced with stable benzyl group	Anti-cancer	Synthetic analogue of natural tubulysins	SK-BR-3	Breast Cancer	MTT assay	IC₅₀ = 12.2 ± 6 pM	72-h	Breast	None
5210	25633717	2015	Str given in figure	KEMTUB10	4	Linear	L	None	fluorine atom in para-position on the phenyl ring	N-tubuvaline fragment replaced with stable benzyl group	Anti-cancer	Synthetic analogue of natural tubulysins	MCF-7/DD	Breast Cancer	MTT assay	IC₅₀ = 68.6 ± 30.1 pM	72-h	Breast	None
5211	25633717	2015	Str given in figure	KEMTUB10	4	Linear	L	None	fluorine atom in para-position on the phenyl ring	N-tubuvaline fragment replaced with stable benzyl group	Anti-cancer	Synthetic analogue of natural tubulysins	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 68 ± 18 pM	72-h	Breast	None
5209	25633717	2015	Str given in figure	KEMTUB10	4	Linear	L	None	fluorine atom in para-position on the phenyl ring	N-tubuvaline fragment replaced with stable benzyl group	Anti-cancer	Synthetic analogue of natural tubulysins	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 30.1 ± 13.2 pM	72-h	Breast	US 8,580,820; US (US 2011/200581).
5175	25974307	2015	NYNQPNS	IturinA	7	Cyclic	L	None	Cyclized; C16 Fatty acid moiety	Cyclized	Lipopeptide	Bacillus megaterium	MDA-MB-468	Breast Cancer	MTT assay	IC₅₀ = 13.30 ± 0.97 μM	48-h	Breast	None
5172	25974307	2015	NYNQPNS	IturinA	7	Cyclic	L	None	Cyclized; C16 Fatty acid moiety	Cyclized	Lipopeptide	Bacillus megaterium	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 7.98 ± 0.19 μM	48-h	Breast	None
5173	25974307	2015	NYNQPNS	IturinA	7	Cyclic	L	None	Cyclized; C16 Fatty acid moiety	Cyclized	Lipopeptide	Bacillus megaterium	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 12.16 ± 0.24 μM	48-h	Breast	None
5174	25974307	2015	NYNQPNS	IturinA	7	Cyclic	L	None	Cyclized; C16 Fatty acid moiety	Cyclized	Lipopeptide	Bacillus megaterium	T-47D	Breast Cancer	MTT assay	IC₅₀ = 26.29 ± 0.78 μM	48-h	Breast	None
5085	24503375	2014	RLGDGCTR	Cyclosaplin	8	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Santalum album L	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 2.06 μg/mL	24-h	Breast	638/KOL/2013
5084	24692199	2014	Wa(D-allo-i)VlL	Baceridin	6	Cyclic	Mix	None	Cyclized	Cyclized	Antimicrobial and Anticancer	culture medium of a plant-associated Bacillus strain	HeLa	Cervical Cancer	MTT assay	IC₅₀ between (1–2 µg/mL)	72-h	Cervix	None
5083	24692199	2014	Wa(D-allo-i)VlL	Baceridin	6	Cyclic	Mix	None	Cyclized	Cyclized	Antimicrobial and Anticancer	culture medium of a plant-associated Bacillus strain	RKO	Colon Cancer	MTT assay	IC₅₀ between (1–2 µg/mL)	72-h	Colon	None
5082	24692199	2014	Wa(D-allo-i)VlL	Baceridin	6	Cyclic	Mix	None	Cyclized	Cyclized	Antimicrobial and Anticancer	culture medium of a plant-associated Bacillus strain	HCT-116 -/- p53	Colon Cancer	MTT assay	IC₅₀ between (1–2 µg/mL)	72-h	Colon	None
5079	24492520	2014	ELLVDLL	Gageostatin C	7	Linear	L	None	Free	(E)-7,9-dimethylundec-2-enoic acid	Antimicrobial	Bacillus subtilis	ACHN	Renal Cancer	Sulforhodamine B assay	GI₅₀ = 12.3 µg/mL	48-h	Kidney	None
5077	24492520	2014	ELLVDLL	Gageostatin C	7	Linear	L	None	Free	(E)-7,9-dimethylundec-2-enoic acid	Antimicrobial	Bacillus subtilis	NCI-H23	Lung Cancer	Sulforhodamine B assay	GI₅₀ = 10.9 µg/mL	48-h	Lung	None
5078	24492520	2014	ELLVDLL	Gageostatin C	7	Linear	L	None	Free	(E)-7,9-dimethylundec-2-enoic acid	Antimicrobial	Bacillus subtilis	NUGC-3	Stomach Cancer	Sulforhodamine B assay	GI₅₀ = 10.5 µg/mL	48-h	Stomach	None
5075	24492520	2014	ELLVDLL	Gageostatin C	7	Linear	L	None	Free	(E)-7,9-dimethylundec-2-enoic acid	Antimicrobial	Bacillus subtilis	HCT-15	Colon Cancer	Sulforhodamine B assay	GI₅₀ = 23.2 µg/mL	48-h	Colon	None
5076	24492520	2014	ELLVDLL	Gageostatin C	7	Linear	L	None	Free	(E)-7,9-dimethylundec-2-enoic acid	Antimicrobial	Bacillus subtilis	PC-3	Prostate Cancer	Sulforhodamine B assay	GI₅₀ = 11.7 µg/mL	48-h	Prostate	None
5073	24492520	2014	ELLVDLL	Gageostatin B	7	Linear	L	None	Free	3-beta-hydroxy-9,11-dimethyltridecanoic acid	Antimicrobial	Bacillus subtilis	ACHN	Renal Cancer	Sulforhodamine B assay	GI₅₀ = 18.4 µg/mL	48-h	Kidney	None
5074	24492520	2014	ELLVDLL	Gageostatin C	7	Linear	L	None	Free	(E)-7,9-dimethylundec-2-enoic acid	Antimicrobial	Bacillus subtilis	MDA-MB-231	Breast Cancer	Sulforhodamine B assay	GI₅₀ = 11.2 µg/mL	48-h	Breast	None
5072	24492520	2014	ELLVDLL	Gageostatin B	7	Linear	L	None	Free	3-beta-hydroxy-9,11-dimethyltridecanoic acid	Antimicrobial	Bacillus subtilis	NUGC-3	Stomach Cancer	Sulforhodamine B assay	GI₅₀ = 13.9 µg/mL	48-h	Stomach	None
5070	24492520	2014	ELLVDLL	Gageostatin B	7	Linear	L	None	Free	3-beta-hydroxy-9,11-dimethyltridecanoic acid	Antimicrobial	Bacillus subtilis	PC-3	Prostate Cancer	Sulforhodamine B assay	GI₅₀ = 19.4 µg/mL	48-h	Prostate	None
5071	24492520	2014	ELLVDLL	Gageostatin B	7	Linear	L	None	Free	3-beta-hydroxy-9,11-dimethyltridecanoic acid	Antimicrobial	Bacillus subtilis	NCI-H23	Lung Cancer	Sulforhodamine B assay	GI₅₀ = 11.7 µg/mL	48-h	Lung	None
5068	24492520	2014	ELLVDLL	Gageostatin B	7	Linear	L	None	Free	3-beta-hydroxy-9,11-dimethyltridecanoic acid	Antimicrobial	Bacillus subtilis	MDA-MB-231	Breast Cancer	Sulforhodamine B assay	GI₅₀ = 16.1 µg/mL	48-h	Breast	None
5069	24492520	2014	ELLVDLL	Gageostatin B	7	Linear	L	None	Free	3-beta-hydroxy-9,11-dimethyltridecanoic acid	Antimicrobial	Bacillus subtilis	HCT-15	Colon Cancer	Sulforhodamine B assay	GI₅₀ = 18.3 µg/mL	48-h	Colon	None
5067	24492520	2014	ELLVDLL	Gageostatin A	7	Linear	L	None	Free	3-beta-hydroxy-11-methyltridecanoic acid	Antimicrobial	Bacillus subtilis	ACHN	Renal Cancer	Sulforhodamine B assay	GI₅₀ = 11.5 µg/mL	48-h	Kidney	None
5065	24492520	2014	ELLVDLL	Gageostatin A	7	Linear	L	None	Free	3-beta-hydroxy-11-methyltridecanoic acid	Antimicrobial	Bacillus subtilis	NCI-H23	Lung Cancer	Sulforhodamine B assay	GI₅₀ = 11.2 µg/mL	48-h	Lung	None
5066	24492520	2014	ELLVDLL	Gageostatin A	7	Linear	L	None	Free	3-beta-hydroxy-11-methyltridecanoic acid	Antimicrobial	Bacillus subtilis	NUGC-3	Stomach Cancer	Sulforhodamine B assay	GI₅₀ = 11.8 µg/mL	48-h	Stomach	None
5064	24492520	2014	ELLVDLL	Gageostatin A	7	Linear	L	None	Free	3-beta-hydroxy-11-methyltridecanoic acid	Antimicrobial	Bacillus subtilis	PC-3	Prostate Cancer	Sulforhodamine B assay	GI₅₀ = 10.8 µg/mL	48-h	Prostate	None
5063	24492520	2014	ELLVDLL	Gageostatin A	7	Linear	L	None	Free	3-beta-hydroxy-11-methyltridecanoic acid	Antimicrobial	Bacillus subtilis	HCT-15	Colon Cancer	Sulforhodamine B assay	GI₅₀ = 11.4 µg/mL	48-h	Colon	None
5062	24492520	2014	ELLVDLL	Gageostatin A	7	Linear	L	None	Free	3-beta-hydroxy-11-methyltridecanoic acid	Antimicrobial	Bacillus subtilis	MDA-MB-231	Breast Cancer	Sulforhodamine B assay	GI₅₀ = 14.9 µg/mL	48-h	Breast	None
5015	24676901	2014	KAQ-Dip-QKQAW	LTX-328	8	Linear	L	Dip = diphenylalanine	Amidation	Free	Antimicrobial	Synthetic peptide	Fem-X	Skin Cancer	MTT/MTS assay	IC₅₀= >350 µM	5–60 Min	Skin	None
5013	24676901	2014	KKWWKKW-Dip-K	LTX-315	9	Linear	L	Dip = diphenylalanine	Amidation	Free	Antimicrobial	Synthetic peptide	A375	Skin Cancer	MTT/MTS assay	IC₅₀=12.7 µM	30-Min	Skin	None
5014	24676901	2014	KKWWKKW-Dip-K	LTX-315	9	Linear	L	Dip = diphenylalanine	Amidation	Free	Antimicrobial	Synthetic peptide	Fem-X	Skin Cancer	MTT/MTS assay	IC₅₀=15.3 µM	30-Min	Skin	None
5012	24676901	2014	KKWWKKW-Dip-K	LTX-315	9	Linear	L	Dip = diphenylalanine	Amidation	Free	Antimicrobial	Synthetic peptide	B16F1	Skin Cancer	MTT/MTS assay	IC₅₀=13.3 µM	30-Min	Skin	None
4671	23085771	2012	Not Available	12c	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=14 µM	Not Available	Blood	None
4669	23085771	2012	Not Available	12a	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=6.1 µM	Not Available	Blood	None
4670	23085771	2012	Not Available	12b	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=27 µM	Not Available	Blood	None
4667	23085771	2012	Not Available	11b	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=19 µM	Not Available	Blood	None
4668	23085771	2012	Not Available	11c	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=7.2 µM	Not Available	Blood	None
4666	23085771	2012	Not Available	11a	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=5.2 µM	Not Available	Blood	None
4664	23085771	2012	Not Available	10b	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=11.4 µM	Not Available	Blood	None
4665	23085771	2012	Not Available	10c	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=6.6 µM	Not Available	Blood	None
4662	23085771	2012	Not Available	9c	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=3.1 µM	Not Available	Blood	None
4663	23085771	2012	Not Available	10a	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=28 µM	Not Available	Blood	None
4660	23085771	2012	Not Available	9a	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=31 µM	Not Available	Blood	None
4661	23085771	2012	Not Available	9b	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=2.3 µM	Not Available	Blood	None
4658	23085771	2012	Not Available	8b	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=>254 µM	Not Available	Blood	None
4659	23085771	2012	Not Available	8c	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=107 µM	Not Available	Blood	None
4657	23085771	2012	Not Available	8a	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=136 µM	Not Available	Blood	None
4655	23085771	2012	Not Available	7b	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=>78 µM	Not Available	Blood	None
4656	23085771	2012	Not Available	7c	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=79 µM	Not Available	Blood	None
4653	23085771	2012	Not Available	6c	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=4.3 µM	Not Available	Blood	None
4654	23085771	2012	Not Available	7a	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=>63 µM	Not Available	Blood	None
4650	23085771	2012	Not Available	5c	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=4.1 µM	Not Available	Blood	None
4651	23085771	2012	Not Available	6a	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=14.4 µM	Not Available	Blood	None
4652	23085771	2012	Not Available	6b	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=11.0 µM	Not Available	Blood	None
4648	23085771	2012	Not Available	5a	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=10.6 µM	Not Available	Blood	None
4649	23085771	2012	Not Available	5b	3	Linear	L	None	Free	Free	Antimicrobial	synthetic b2,2-amino acid derivatives	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀=7.1 µM	Not Available	Blood	None
4618	20964334	2010	KWKWKW	Dex-(KW)3	6	Linear	L	Dextran	Amidation	Dextran	Anticancer	Synthetic	PC-3	Prostate Cancer	MTT/MTS assay	at 10 µM 60% viablity	Not Available	Prostate	None
4619	20964334	2010	KWKWKW	Dex-(KW)3	6	Linear	L	Dextran	Amidation	Dextran	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT/MTS assay	at 10 µM 35-40% viablity	Not Available	Breast	None
4616	20802991	2010	CSSRTMHHC	Peptide-20	9	Cyclic(C1-C9)	L	None	Free	Free	Antitumor	Synthetic Peptide	Skmel-25	Skin Cancer	MTT/MTS assay	at 100 µM 55^-60% viablity	48-h	Skin	None
4617	20802991	2010	CSSRTMHHC	Peptide-20	9	Cyclic(C1-C9)	L	None	Free	Free	Antitumor	Synthetic Peptide	Skmel-28	Skin Cancer	MTT/MTS assay	at 100 µM 35-40% viablity	48-h	Skin	None
4614	20802991	2010	CSSRTMHHC	Peptide-20	9	Cyclic(C1-C9)	L	None	Free	Free	Antitumor	Synthetic Peptide	B16F10-Nex 2	Skin Cancer	MTT/MTS assay	at 100 µM 50% viablity	48-h	Skin	None
4615	20802991	2010	CSSRTMHHC	Peptide-20	9	Cyclic(C1-C9)	L	None	Free	Free	Antitumor	Synthetic Peptide	A-2058	Skin Cancer	MTT/MTS assay	at 100 µM 30% viablity	48-h	Skin	None
4612	20802991	2010	CSSRTMHHC	Peptide-20	9	Cyclic(C1-C9)	L	None	Free	Free	Antitumor	Synthetic Peptide	MDA-MB-231	Breast Cancer	MTT/MTS assay	at 100 µM 55% viablity	48-h	Breast	None
4613	20802991	2010	CSSRTMHHC	Peptide-20	9	Cyclic(C1-C9)	L	None	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	at 100 µM 50% viablity	48-h	Cervix	None
4611	20802991	2010	CSSRTMHHC	Peptide-20	9	Cyclic(C1-C9)	L	None	Free	Free	Antitumor	Synthetic Peptide	HL-60	Leukemia Cancer	MTT/MTS assay	at 100 µM 90% viablity	48-h	Blood	None
4429	15253156, 18957441	2004	ACSAG	EP5-1	5	Not Available	L	None	Free	Free	Anticancer	redworms, brandling worms, "tiger worms" and red wiggler worms, Eisenia foetida	Not Available	Fibrosarcoma	Not Available	Not Available	Not Available	Fibrous connective tissue	None
4365	21882228, 18957441	2012	AWKLFDDGV	Cr-ACP1	9	Not Available	L	None	Free	Free	Antibacterial	Seeds,Cycas revoluta	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	None
4224	16091933	2005	YSL	Tyroserleutide	3	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	BEL-7402	Liver Cancer	MTT/MTS assay	20.8% cytotoxic at 1 µg/ml	96-h	Liver	None
4225	16091933	2005	YSL	Tyroserleutide	3	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	BEL-7402	Liver Cancer	MTT/MTS assay	33.8% cytotoxic at 10 µg/ml	96-h	Liver	None
4226	16091933	2005	YSL	Tyroserleutide	3	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	BEL-7402	Liver Cancer	MTT/MTS assay	35.6% cytotoxic at 100 µg/ml	96-h	Liver	None
4221	16091933	2005	YSL	Tyroserleutide	3	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	B16-F10	Skin Cancer	MTT/MTS assay	53.0% cytotoxic at 10 µg/ml	96-h	Skin	None
4222	16091933	2005	YSL	Tyroserleutide	3	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	B16-F10	Skin Cancer	MTT/MTS assay	61.2% cytotoxic at 100 µg/ml	96-h	Skin	None
4223	16091933	2005	YSL	Tyroserleutide	3	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	BEL-7402	Liver Cancer	MTT/MTS assay	39.0% cytotoxic at 0.1 µg/ml	96-h	Liver	None
4219	16091933	2005	YSL	Tyroserleutide	3	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	B16-F10	Skin Cancer	MTT/MTS assay	49.4% cytotoxic at 0.1 µg/ml	96-h	Skin	None
4220	16091933	2005	YSL	Tyroserleutide	3	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	B16-F10	Skin Cancer	MTT/MTS assay	51.2% cytotoxic at 1 µg/ml	96-h	Skin	None
4183	14991605	2004	KIFGSLAFL	p369-CTL-A2xFVB	9	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	N202.A2	Tumor	Peptide dose curve assay	92% Inhibition at 10^-6 M	Not Available	Not Available	None
4184	15313924	2004	HHPHG	HHPHG	5	Linear	L	None	Free	Free	Antiangiogenesis and Antitumor	Synthetic Peptide	Not Available	Tumor	Tropomyosin binding assay	IC₅₀=92 µM	Not Available	Not Available	None
4182	14991605	2004	KIFGSLAFL	p369-CTL-A2xFVB	9	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	N202.A2	Tumor	Peptide dose curve assay	85% Inhibition at 10^-7 M	Not Available	Not Available	None
4180	14991605	2004	KIFGSLAFL	p369-CTL-A2xFVB	9	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	N202.A2	Tumor	Peptide dose curve assay	25% Inhibition at 10^-9 M	Not Available	Not Available	None
4181	14991605	2004	KIFGSLAFL	p369-CTL-A2xFVB	9	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	N202.A2	Tumor	Peptide dose curve assay	80% Inhibition at 10^-8 M	Not Available	Not Available	None
4179	14991605	2004	KIFGSLAFL	p369-CTL-A2xFVB	9	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	N202.A2	Tumor	Peptide dose curve assay	8% Inhibition at 10^-10 M	Not Available	Not Available	None
4178	14991605	2004	KIFGSLAFL	p369-CTL-A2xneu	9	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	N202.A2	Tumor	Peptide dose curve assay	20% Inhibition at 10^-6 M	Not Available	Not Available	None
4177	14991605	2004	KIFGSLAFL	p369-CTL-A2xneu	9	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	N202.A2	Tumor	Peptide dose curve assay	10% Inhibition at 10^-7 M	Not Available	Not Available	None
4176	14991605	2004	KIFGSLAFL	p369-CTL-A2xneu	9	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	N202.A2	Tumor	Peptide dose curve assay	5% Inhibition at 10^-8 M	Not Available	Not Available	None
4175	14991605	2004	KIFGSLAFL	p369-CTL-A2xneu	9	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	N202.A2	Tumor	Peptide dose curve assay	1% Inhibition at 10^-9 M	Not Available	Not Available	None
4174	14991605	2004	KIFGSLAFL	p369-CTL-A2xneu	9	Linear	L	None	Free	Free	Antitumor	Synthetic Peptide	N202.A2	Tumor	Peptide dose curve assay	0.1% Inhibition at 10^-10 M	Not Available	Not Available	None
4025	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	47.0% inhibition at 10^-3M	31.92-Min	Colon	None
4026	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	2.2% inhibition at 10^-6M	31.92-Min	Breast	None
4027	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	7.1% inhibition at 10^-5M	31.92-Min	Breast	None
4028	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	6.9% inhibition at 10^-4M	31.92-Min	Breast	None
4029	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	25.9% inhibition at 10^-3M	31.92-Min	Breast	None
4021	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	70.7% inhibition at 10^-5M	31.92-Min	Skin	None
4022	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	34.4% inhibition at 10^-3M	31.92-Min	Skin	None
4023	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	9.2% inhibition at 10^-3M	31.92-Min	Colon	None
4024	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	11.08% inhibition at 10^-5M	31.92-Min	Colon	None
4016	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	29.9% inhibition at 10^-3M	23.03-Min	Breast	None
4017	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	3.9% inhibition at 10^-5M	31.92-Min	Larynx	None
4018	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	45% inhibition at 10^-3M	31.92-Min	Larynx	None
4019	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	9.3% inhibition at 10^-3M	31.92-Min	Cervix	None
4020	16722632	2006	YGGFMA*	23	6	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	4.1% inhibition at 10^-6M	31.92-Min	Skin	None
4012	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	10.9% inhibition at 10^-5M	23.03-Min	Colon	None
4013	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	12.1% inhibition at 10^-4M	23.03-Min	Colon	None
4014	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	8.1% inhibition at 10^-3M	23.03-Min	Colon	None
4015	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	9.6% inhibition at 10^-4M	23.03-Min	Breast	None
4008	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	13.1% inhibition at 10^-5M	23.03-Min	Colon	None
4009	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	14.6% inhibition at 10^-4M	23.03-Min	Colon	None
4010	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	38.4% inhibition at 10^-3M	23.03-Min	Colon	None
4011	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	17.7% inhibition at 10^-6M	23.03-Min	Colon	None
4003	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	16.2% inhibition at 10^-6M	23.03-Min	Colon	None
4004	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	6.6% inhibition at 10^-5M	23.03-Min	Colon	None
4005	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	5.1% inhibition at 10^-4M	23.03-Min	Colon	None
4006	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	14.5% inhibition at 10^-3M	23.03-Min	Colon	None
4007	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	26.4% inhibition at 10^-6M	23.03-Min	Colon	None
3999	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	2.4% inhibition at 10^-6M	23.03-Min	Skin	None
4000	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	4.5% inhibition at 10^-5M	23.03-Min	Skin	None
4001	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	11.4% inhibition at 10^-4M	23.03-Min	Skin	None
4002	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	23.2% inhibition at 10^-3M	23.03-Min	Skin	None
3994	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	44.5% inhibition at 10^-3M	23.03-Min	Larynx	None
3995	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	8.5% inhibition at 10^-6M	23.03-Min	Cervix	None
3996	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	9.5% inhibition at 10^-5M	23.03-Min	Cervix	None
3997	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	15.4% inhibition at 10^-4M	23.03-Min	Cervix	None
3998	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	24.1% inhibition at 10^-3M	23.03-Min	Cervix	None
3991	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	13.7% inhibition at 10^-6M	23.03-Min	Larynx	None
3992	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	25.8% inhibition at 10^-5M	23.03-Min	Larynx	None
3993	16722632	2006	YA*GFM	18	5	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	34.7% inhibition at 10^-4M	23.03-Min	Larynx	None
3988	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	18.5% inhibition at 10^-4M	26.70-Min	Colon	None
3989	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	10.6% inhibition at 10^-3M	26.70-Min	Colon	None
3990	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	22.8% inhibition at 10^-3M	26.70-Min	Breast	None
3986	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	3.0% inhibition at 10^-6M	26.70-Min	Colon	None
3987	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	8.4% inhibition at 10^-5M	26.70-Min	Colon	None
3984	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	24.7% inhibition at 10^-4M	26.70-Min	Colon	None
3985	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	29.0% inhibition at 10^-3M	26.70-Min	Colon	None
3981	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	23.7% inhibition at 10^-3M	26.70-Min	Colon	None
3982	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	12.2% inhibition at 10^-6M	26.70-Min	Colon	None
3983	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	15.5% inhibition at 10^-5M	26.70-Min	Colon	None
3978	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	3.3% inhibition at 10^-6M	26.70-Min	Colon	None
3979	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	11.0% inhibition at 10^-5M	26.70-Min	Colon	None
3980	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	7.9% inhibition at 10^-4M	26.70-Min	Colon	None
3976	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	2.4% inhibition at 10^-4M	26.70-Min	Skin	None
3977	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	18.3% inhibition at 10^-3M	26.70-Min	Skin	None
3971	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	10.2% inhibition at 10^-5M	26.70-Min	Cervix	None
3972	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	13.3% inhibition at 10^-4M	26.70-Min	Cervix	None
3973	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	28.0% inhibition at 10^-3M	26.70-Min	Cervix	None
3974	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	0.8% inhibition at 10^-6M	26.70-Min	Skin	None
3975	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	1.4% inhibition at 10^-5M	26.70-Min	Skin	None
3970	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	4.9% inhibition at 10^-6M	26.70-Min	Cervix	None
3969	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	36.1% inhibition at 10^-3M	26.70-Min	Larynx	None
3968	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	16.8% inhibition at 10^-4M	26.70-Min	Larynx	None
3967	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	10.1% inhibition at 10^-5M	26.70-Min	Larynx	None
3966	16722632	2006	YA*GFM	17	5	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	1.0% inhibition at 10^-6M	26.70-Min	Larynx	None
3964	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	8.6% inhibition at 10^-3M	10.79-Min	Colon	None
3965	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	15.6% inhibition at 10^-3M	10.79-Min	Breast	None
3962	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	6.9% inhibition at 10^-5M	10.79-Min	Colon	None
3963	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	8.1% inhibition at 10^-4M	10.79-Min	Colon	None
3959	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	13.5% inhibition at 10^-4M	10.79-Min	Colon	None
3960	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	25.3% inhibition at 10^-3M	10.79-Min	Colon	None
3961	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	8.1% inhibition at 10^-6M	10.79-Min	Colon	None
3957	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	17.0% inhibition at 10^-6M	10.79-Min	Colon	None
3958	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	13.5% inhibition at 10^-5M	10.79-Min	Colon	None
3955	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	12.4% inhibition at 10^-4M	10.79-Min	Colon	None
3956	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	22.4% inhibition at 10^-3M	10.79-Min	Colon	None
3952	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	19.4% inhibition at 10^-3M	10.79-Min	Skin	None
3953	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	7.6% inhibition at 10^-6M	10.79-Min	Colon	None
3954	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	3.8% inhibition at 10^-5M	10.79-Min	Colon	None
3949	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	28.2% inhibition at 10^-3M	10.79-Min	Cervix	None
3950	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	1.2% inhibition at 10^-5M	10.79-Min	Skin	None
3951	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	3.3% inhibition at 10^-4M	10.79-Min	Skin	None
3947	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	11.7% inhibition at 10^-5M	10.79-Min	Cervix	None
3948	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	11.6% inhibition at 10^-4M	10.79-Min	Cervix	None
3944	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	12.6% inhibition at 10^-4M	10.79-Min	Larynx	None
3945	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	26.4% inhibition at 10^-3M	10.79-Min	Larynx	None
3946	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	11.0% inhibition at 10^-6M	10.79-Min	Cervix	None
3942	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	4.6% inhibition at 10^-6M	10.79-Min	Larynx	None
3943	16722632	2006	YRA*G	16	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	4.9% inhibition at 10^-5M	10.79-Min	Larynx	None
3940	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	6.2% inhibition at 10^-3M	9.53-Min	Colon	None
3941	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	21.2% inhibition at 10^-3M	9.53-Min	Breast	None
3937	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	2.2% inhibition at 10^-6M	9.53-Min	Colon	None
3938	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	4.2% inhibition at 10^-5M	9.53-Min	Colon	None
3939	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	6.4% inhibition at 10^-4M	9.53-Min	Colon	None
3935	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	14.4% inhibition at 10^-4M	9.53-Min	Colon	None
3936	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	23.4% inhibition at 10^-3M	9.53-Min	Colon	None
3932	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	15.7% inhibition at 10^-3M	9.53-Min	Colon	None
3933	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	13.6% inhibition at 10^-6M	9.53-Min	Colon	None
3934	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	20.4% inhibition at 10^-5M	9.53-Min	Colon	None
3930	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	7.4% inhibition at 10^-5M	9.53-Min	Colon	None
3931	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	9.5% inhibition at 10^-4M	9.53-Min	Colon	None
3927	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	5.9% inhibition at 10^-4M	9.53-Min	Skin	None
3928	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	17.9% inhibition at 10^-3M	9.53-Min	Skin	None
3929	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	5.4% inhibition at 10^-6M	9.53-Min	Colon	None
3925	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	1.6% inhibition at 10^-6M	9.53-Min	Skin	None
3926	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	2.9% inhibition at 10^-5M	9.53-Min	Skin	None
3922	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	7.3% inhibition at 10^-5M	9.53-Min	Cervix	None
3923	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	9.9% inhibition at 10^-4M	9.53-Min	Cervix	None
3924	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	28.2% inhibition at 10^-3M	9.53-Min	Cervix	None
3920	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	26.7% inhibition at 10^-3M	9.53-Min	Larynx	None
3921	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	9.8% inhibition at 10^-6M	9.53-Min	Cervix	None
3917	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	2.7% inhibition at 10^-6M	9.53-Min	Larynx	None
3918	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	2.0% inhibition at 10^-5M	9.53-Min	Larynx	None
3919	16722632	2006	YSA*G	15	4	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	18.8% inhibition at 10^-4M	9.53-Min	Larynx	None
3915	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	7.7% inhibition at 10^-4M	14.05-Min	Breast	None
3916	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	18.7% inhibition at 10^-3M	14.05-Min	Breast	None
3913	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	10.7% inhibition at 10^-6	14.05-Min	Colon	None
3914	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	10.0% inhibition at 10^-5	14.05-Min	Colon	None
3910	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	8.3% inhibition at 10^-5	14.05-Min	Colon	None
3911	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	10.5% inhibition at 10^-4	14.05-Min	Colon	None
3912	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	21.8% inhibition at 10^-3	14.05-Min	Colon	None
3908	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	7.3% inhibition at 10^-3	14.05-Min	Skin	None
3909	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	0.7% inhibition at 10^-6	14.05-Min	Colon	None
3905	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	3.0% inhibition at 10^-6	14.05-Min	Skin	None
3906	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	4.7% inhibition at 10^-5	14.05-Min	Skin	None
3907	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	2.7% inhibition at 10^-4	14.05-Min	Skin	None
3903	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	11.0% inhibition at 10^-4	14.05-Min	Cervix	None
3904	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	20.5% inhibition at 10^-3	14.05-Min	Cervix	None
3901	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	7.2% inhibition at 10^-6	14.05-Min	Cervix	None
3902	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	17.1% inhibition at 10^-5	14.05-Min	Cervix	None
3898	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	4.9% inhibition at 10^-5	14.05-Min	Larynx	None
3899	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	1.9% inhibition at 10^-4	14.05-Min	Larynx	None
3900	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	16.2% inhibition at 10^-3	14.05-Min	Larynx	None
3896	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	17.8% inhibition at 10^-3	12.46-Min	Breast	None
3897	16722632	2006	YSA*	10	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	8.5% inhibition at 10^-6	14.05-Min	Larynx	None
3893	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	14.5% inhibition at 10^-3	12.46-Min	Colon	None
3894	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	1.1% inhibition at 10^-5	12.46-Min	Breast	None
3895	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	1.2% inhibition at 10^-4	12.46-Min	Breast	None
3892	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	8.4% inhibition at 10^-4	12.46-Min	Colon	None
3891	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	16.5% inhibition at 10^-5	12.46-Min	Colon	None
3890	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	3.7% inhibition at 10^-6	12.46-Min	Colon	None
3889	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	17.9% inhibition at 10^-3	12.46-Min	Colon	None
3888	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	11.8% inhibition at 10^-4	12.46-Min	Colon	None
3887	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	21.9% inhibition at 10^-5	12.46-Min	Colon	None
3886	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	10.5% inhibition at 10^-6	12.46-Min	Colon	None
3885	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	20.8% inhibition at 10^-3	12.46-Min	Colon	None
3884	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	3.4% inhibition at 10^-4	12.46-Min	Colon	None
3883	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	8.9% inhibition at 10^-5	12.46-Min	Colon	None
3882	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	4.9% inhibition at 10^-6	12.46-Min	Colon	None
3881	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	7.3% inhibition at 10^-3	12.46-Min	Skin	None
3880	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	3.9% inhibition at 10^-5	12.46-Min	Skin	None
3879	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	14.8% inhibition at 10^-3	12.46-Min	Cervix	None
3877	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	6.1% inhibition at 10^-5	12.46-Min	Cervix	None
3878	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	3.1% inhibition at 10^-4	12.46-Min	Cervix	None
3876	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	7.5% inhibition at 10^-6	12.46-Min	Cervix	None
3875	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	21.2% inhibition at 10^-3	12.46-Min	Larynx	None
3874	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	8.2% inhibition at 10^-4	12.46-Min	Larynx	None
3873	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	6.4% inhibition at 10^-5	12.46-Min	Larynx	None
3872	16722632	2006	YSA*	9	3	Linear	L	A* = Cα -dialkylated glycine (Aaa2,2 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	6.2% inhibition at 10^-6	12.46-Min	Larynx	None
3871	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	7.5% inhibition at 10^-4	12.81-Min	Breast	None
3870	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	MCF-7	Breast Cancer	MTT/MTS assay	2.4% inhibition at 10^-5	12.81-Min	Breast	None
3868	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	18.9% inhibition at 10^-4	12.81-Min	Colon	None
3869	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	26.4% inhibition at 10^-3	12.81-Min	Colon	None
3867	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	22.7% inhibition at 10^-5	12.81-Min	Colon	None
3866	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	CaCo-2	Colon Cancer	MTT/MTS assay	3.5% inhibition at 10^-6	12.81-Min	Colon	None
3864	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	28.1% inhibition at 10^-4	12.81-Min	Colon	None
3865	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	58.2% inhibition at 10^-3	12.81-Min	Colon	None
3863	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	16.5% inhibition at 10^-5	12.81-Min	Colon	None
3862	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	SW-620	Colon Cancer	MTT/MTS assay	12.9% inhibition at 10^-6	12.81-Min	Colon	None
3861	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	26.5% inhibition at 10^-3	12.81-Min	Colon	None
3859	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	1.6% inhibition at 10^-5	12.81-Min	Colon	None
3860	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	5.4% inhibition at 10^-4	12.81-Min	Colon	None
3857	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	14% inhibition at 10^-3	12.81-Min	Skin	None
3858	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HT-29	Colon Cancer	MTT/MTS assay	9.8% inhibition at 10^-6	12.81-Min	Colon	None
3856	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	7.5% inhibition at 10^-4	12.81-Min	Skin	None
3855	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	14% inhibition at 10^-5	12.81-Min	Skin	None
3854	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HBL	Skin Cancer	MTT/MTS assay	6.5% inhibition at 10^-6	12.81-Min	Skin	None
3853	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	36.1% inhibition at 10^-3	12.81-Min	Not Available	None
3852	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	8.2% inhibition at 10^-4	12.81-Min	Not Available	None
3851	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HeLa	Cervical Cancer	MTT/MTS assay	10% inhibition at 10^-5	12.81-Min	Not Available	None
3850	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	30.4% inhibition at 10^-3	12.81-Min	Not Available	None
3849	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	24.9% inhibition at 10^-4	12.81-Min	Not Available	None
3848	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	19.7% inhibition at 10^-5	12.81-Min	Not Available	None
3847	16722632	2006	YA*	8	2	Linear	L	A* = Cαα -dialkylated glycine (Aaa1,1 )	Free	Free	Antitumor	Synthetic Peptide	HEp-2	Larynx Cancer	MTT/MTS assay	14.2% inhibition at 10^-6	12.81-Min	Not Available	None
3788	22933412	2012	KW β2,2KK	c8	5	Linear	L	(2,2-di(4-[trifluoromethyl]benzyl)-3-amino-propionic acid)	Amidation	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 226±21 µMol/L	NA	Blood	None
3787	22933412	2012	KK β2,2WKK	c7	6	Linear	L	(2,2-di(4-[trifluoromethyl]benzyl)-3-amino-propionic acid)	Amidation	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 157±30 µMol/L	NA	Blood	None
3786	22933412	2012	KW β2,2WKK	c6	6	Linear	L	(2,2-di(4-[trifluoromethyl]benzyl)-3-amino-propionic acid)	Amidation	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 26±2 µMol/L	NA	Blood	None
3785	22933412	2012	KKW β2,2WKK	c5	7	Linear	L	(2,2-di(4-[trifluoromethyl]benzyl)-3-amino-propionic acid)	Amidation	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 23±3 µMol/L	NA	Blood	None
3784	22933412	2012	KW β2,2KK	c4	5	Linear	L	(2,2-di(naphthalen-2-ylmethyl)-3-amino-propionic acid)	Amidation	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 99±15 µMol/L	NA	Blood	None
3783	22933412	2012	KK β2,2WKK	c3	6	Linear	L	(2,2-di(naphthalen-2-ylmethyl)-3-amino-propionic acid)	Amidation	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 92±2 µMol/L	NA	Blood	None
3782	22933412	2012	KW β2,2WKK	c2	6	Linear	L	(2,2-di(naphthalen-2-ylmethyl)-3-amino-propionic acid)	Amidation	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 1.71±0.6 µMol/L	NA	Blood	None
3781	22933412	2012	KKWβ2,2WKK	c1	7	Linear	L	(2,2-di(naphthalen-2-ylmethyl)-3-amino-propionic acid)	Amidation	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 22±5 µMol/L	NA	Blood	None
3780	22933412	2012	KW β2,2KK	c8	5	Cyclic	L	(2,2-di(4-[trifluoromethyl]benzyl)-3-amino-propionic acid)	Free	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 20±2 µMol/L	NA	Blood	None
3779	22933412	2012	KK β2,2WKK	c7	6	Cyclic	L	(2,2-di(4-[trifluoromethyl]benzyl)-3-amino-propionic acid)	Free	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 16±5 µMol/L	NA	Blood	None
3778	22933412	2012	KW β2,2WKK	c6	6	Cyclic	L	(2,2-di(4-[trifluoromethyl]benzyl)-3-amino-propionic acid)	Free	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 8±1 µMol/L	NA	Blood	None
3775	22933412	2012	KK β2,2WKK	c3	6	Cyclic	L	(2,2-di(naphthalen-2-ylmethyl)-3-amino-propionic acid)	Free	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 15±2 µMol/L	NA	Blood	None
3776	22933412	2012	KW β2,2KK	c4	5	Cyclic	L	(2,2-di(naphthalen-2-ylmethyl)-3-amino-propionic acid)	Free	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 12.6±0.6 µMol/L	NA	Blood	None
3777	22933412	2012	KKW β2,2WKK	c5	7	Cyclic	L	(2,2-di(4-[trifluoromethyl]benzyl)-3-amino-propionic acid)	Free	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 11±2 µMol/L	NA	Blood	None
3773	22933412	2012	KKWβ2,2WKK	c1	7	Cyclic	L	(2,2-di(naphthalen-2-ylmethyl)-3-amino-propionic acid)	Free	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 10±2 µMol/L	NA	Blood	None
3774	22933412	2012	KW β2,2WKK	c2	6	Cyclic	L	(2,2-di(naphthalen-2-ylmethyl)-3-amino-propionic acid)	Free	Free	Anticancer	KKWβ2,2WKK	Ramos	Lymphoma Cancer	MTT/MTS assay	IC₅₀= 7.9±0.3 µMol/L	NA	Blood	None
3723	9815815	1997	fAYwKAT	Lan-7	7	Cyclic	Mix	A*=Lanthionine bridge between Alanine	Free	Free	Antitumor	Analogue of TT-232	UMSCC10b	Head and Neck Cancer	Sulforhodamine B assay	IC₅₀= 27.69±2.17 µM	48-h	Head and Neck	None
3724	9815815	1997	fAYwKAT	Lan-7	7	Cyclic	Mix	A*=Lanthionine bridge between Alanine	Free	Free	Antitumor	Analogue of TT-232	HCT-116	Colon Cancer	Sulforhodamine B assay	IC₅₀= 29.97±1.19 µM	72-h	Colon	None
3725	9815815	1997	fAYwKAT	Lan-7	7	Cyclic	Mix	A*=Lanthionine bridge between Alanine	Free	Free	Antitumor	Analogue of TT-232	HEC-59	Endometrial cancer	Sulforhodamine B assay	IC₅₀= 36.81±0.40 µM	72-h	Endometrial	None
3721	9815815	1997	fAYwKAT	Lan-7	7	Cyclic	Mix	A*=Lanthionine bridge between Alanine	Free	Free	Antitumor	Analogue of TT-232	Ovary tumor cellline	Ovarian Cancer	Sulforhodamine B assay	IC₅₀= 16.93±1.84 µM	48-h	Ovary	None
3722	9815815	1997	fAYwKAT	Lan-7	7	Cyclic	Mix	A*=Lanthionine bridge between Alanine	Free	Free	Antitumor	Analogue of TT-232	UMSCC10b	Head and Neck Cancer	Sulforhodamine B assay	IC₅₀= 33.88±1.98 µM	24-h	Head and Neck	None
3720	9815815	1997	fAYwKAT	Lan-7	7	Cyclic	Mix	A*=Lanthionine bridge between Alanine	Free	Free	Antitumor	Analogue of TT-232	Ovary tumor cellline	Ovarian Cancer	Sulforhodamine B assay	IC₅₀=17.05±6.61 µM	24-h	Ovary	None
3342	23533710	2013	YPFPG	β-Casomorphins 5 f(60_64)	4	Linear	L	None	Amidation	Free	Immunomodulant, Antihypertensive, Antimicrobial,Antiviral, and Antioxidant	Bovine milk	AZ-97	Colon Cancer	MTT/MTS assay	Inhibition at 9-11g/l	NA	Colon	None
3343	23533710	2013	RYLGYL	αs1-casein f(90_95)	6	Linear	L	None	Amidation	Free	Immunomodulant, Antihypertensive, Antimicrobial,Antiviral, and Antioxidant	Bovine milk	AZ-97	Colon Cancer	MTT/MTS assay	Inhibition at 12-15g/l	NA	Colon	None
3344	23533710	2013	PPPEE	Caseinphosphopeptides	5	Linear	L	None	Amidation	Free	Immunomodulant, Antihypertensive, Antimicrobial,Antiviral, and Antioxidant	Bovine milk	AZ-97	Colon Cancer	MTT/MTS assay	Inhibition at 24-28g/l	NA	Colon	None
3313	21453492	2011	OOW-Dip-OOWWO	LTX-318	9	Linear	L	Dip = diphenylalanine, O=ornithine	Amidation	Free	Antimicrobial	Synthetic peptide	Kelly	Brain Tumor	MTT/MTS assay	IC₅₀ =78 ± 7 µM	30-Min	Brain	None
3312	21453492	2011	OOW-Dip-OOWWO	LTX-318	9	Linear	L	Dip = diphenylalanine, O=ornithine	Amidation	Free	Antimicrobial	Synthetic peptide	MT-1	Breast Cancer	MTT/MTS assay	IC₅₀ =216 ± 36 µM	30-Min	Breast	None
3311	21453492	2011	OOW-Dip-OOWWO	LTX-318	9	Linear	L	Dip = diphenylalanine, O=ornithine	Amidation	Free	Antimicrobial	Synthetic peptide	HT-29	Colon Cancer	MTT/MTS assay	IC₅₀ =248 ± 5 µM	30-Min	Colon	None
3309	21453492	2011	KKWWKKW-Dip-K	LTX-315	9	Linear	L	Dip = diphenylalanine	Amidation	Free	Antimicrobial	Synthetic peptide	MT-1	Breast Cancer	MTT/MTS assay	IC₅₀ =31 ± 3 µM	30-Min	Breast	None
3310	21453492	2011	KKWWKKW-Dip-K	LTX-315	9	Linear	L	Dip = diphenylalanine	Amidation	Free	Antimicrobial	Synthetic peptide	Kelly	Brain Tumor	MTT/MTS assay	IC₅₀ =14 ± 1 µM	30-Min	Brain	None
3308	21453492	2011	KKWWKKW-Dip-K	LTX-315	9	Linear	L	Dip = diphenylalanine	Amidation	Free	Antimicrobial	Synthetic peptide	HT-29	Colon Cancer	MTT/MTS assay	IC₅₀ =38 ± 3 µM	30-Min	Colon	None
3307	21453492	2011	WKKW-Dip-KKWK	LTX-302	9	Linear	L	Dip = diphenylalanine	Amidation	Free	Antimicrobial	Synthetic peptide	Kelly	Brain Tumor	MTT/MTS assay	IC₅₀ =28 ± 0 µM	30-Min	Brain	None
3306	21453492	2011	WKKW-Dip-KKWK	LTX-302	9	Linear	L	Dip = diphenylalanine	Amidation	Free	Antimicrobial	Synthetic peptide	MT-1	Breast Cancer	MTT/MTS assay	IC₅₀ =73 ± 2 µM	30-Min	Breast	None
3305	21453492	2011	WKKW-Dip-KKWK	LTX-302	9	Linear	L	Dip = diphenylalanine	Amidation	Free	Antimicrobial	Synthetic peptide	HT-29	Colon Cancer	MTT/MTS assay	IC₅₀ =75 ± 5 µM	30-Min	Colon	None
3215	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	MDBK	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3213	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	MDBK	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3214	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	MDBK	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3211	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	MDBK	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3212	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	MDBK	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3210	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	Vero	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3208	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	CEF	Tumor	MTT/MTS assay	NA	48-h	Not Available	None
3204	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	MDBK	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3205	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	MDBK	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3203	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	MDBK	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3201	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	MDBK	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3202	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	MDBK	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3198	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	CEF	Tumor	MTT/MTS assay	NA	48-h	Not Available	None
3200	22184121	2011	MTLTG	BPP-II	5	Linear	L	None	Free	Free	Antitumor	Immunomodulatory bursal-derived Pentapeptide-II	Vero	Renal Cancer	MTT/MTS assay	NA	48-h	Renal	None
3197	17787026	2007	(K-Aib-C(CH2CO-2'-Pac))4	Tetramer of peptide-paclitaxel conjugate	3	Linear	L	Aib = 1-amino-isobutyric acid ,Pac = Paclitaxel	Amidation	Acetylation	Anticancer	Synthetic peptide paclitaxel conjugate	MCF-7	Breast Cancer	MTT/MTS assay	IC₅₀ =0.64nM	24-h	Breast	None
3195	17787026	2007	(K-Aib-C(CH2CO-2'-Pac))4	Tetramer of peptide-paclitaxel conjugate	3	Linear	L	Aib = 1-amino-isobutyric acid ,Pac = Paclitaxel	Amidation	Acetylation	Anticancer	Synthetic peptide paclitaxel conjugate	HeLa	Cervical Cancer	MTT/MTS assay	IC₅₀ =0.96nM	24-h	Cervix	None
3196	17787026	2007	(K-Aib-C(CH2CO-2'-Pac))4	Tetramer of peptide-paclitaxel conjugate	3	Linear	L	Aib = 1-amino-isobutyric acid ,Pac = Paclitaxel	Amidation	Acetylation	Anticancer	Synthetic peptide paclitaxel conjugate	DU	Prostate Cancer	MTT/MTS assay	IC₅₀ =1.30nM	24-h	Prostate	None
3194	17787026	2007	(K-Aib-C(CH2CO-2'-Pac))3	Trimer of peptide-paclitaxel conjugate	3	Linear	L	Aib = 1-amino-isobutyric acid ,Pac = Paclitaxel	Amidation	Acetylation	Anticancer	Synthetic peptide paclitaxel conjugate	MCF-7	Breast Cancer	MTT/MTS assay	IC₅₀ =3.00nM	24-h	Breast	None
3192	17787026	2007	(K-Aib-C(CH2CO-2'-Pac))3	Trimer of peptide-paclitaxel conjugate	3	Linear	L	Aib = 1-amino-isobutyric acid ,Pac = Paclitaxel	Amidation	Acetylation	Anticancer	Synthetic peptide paclitaxel conjugate	HeLa	Cervical Cancer	MTT/MTS assay	IC₅₀ =1.70nM	24-h	Cervix	None
3193	17787026	2007	(K-Aib-C(CH2CO-2'-Pac))3	Trimer of peptide-paclitaxel conjugate	3	Linear	L	Aib = 1-amino-isobutyric acid ,Pac = Paclitaxel	Amidation	Acetylation	Anticancer	Synthetic peptide paclitaxel conjugate	DU	Prostate Cancer	MTT/MTS assay	IC₅₀ =3.88nM	24-h	Prostate	None
3191	17787026	2007	(K-Aib-C(CH2CO-2'-Pac))4	Dimer of peptide-paclitaxel conjugate	3	Linear	L	Aib = 1-amino-isobutyric acid ,Pac = Paclitaxel	Amidation	Acetylation	Anticancer	Synthetic peptide paclitaxel conjugate	MCF-7	Breast Cancer	MTT/MTS assay	IC₅₀ =0.62nM	24-h	Breast	None
3190	17787026	2007	(K-Aib-C(CH2CO-2'-Pac))3	Dimer of peptide-paclitaxel conjugate	3	Linear	L	Aib = 1-amino-isobutyric acid ,Pac = Paclitaxel	Amidation	Acetylation	Anticancer	Synthetic peptide paclitaxel conjugate	DU	Prostate Cancer	MTT/MTS assay	IC₅₀ =2.85nM	24-h	Prostate	None
3189	17787026	2007	(K-Aib-C(CH2CO-2'-Pac))2	Dimer of peptide-paclitaxel conjugate	3	Linear	L	Aib = 1-amino-isobutyric acid ,Pac = Paclitaxel	Amidation	Acetylation	Anticancer	Synthetic peptide paclitaxel conjugate	HeLa	Cervical Cancer	MTT/MTS assay	IC₅₀ =1.31nM	24-h	Cervix	None
3164	23301519	2013	RWRWRWRW	linear (RW)4-Dox	8	Linear	L	Doxorubicin (Dox) which is anthracycline attached with linker to CPP [W(RW)4 ]	Free	Free	Anticancer	Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP	MDA-MB-468	Breast Cancer	MTT/MTS assay	60-74% antiproliferative activity at 1 µM	72 to 120-h	Breast	None
3163	23301519	2013	RWRWRWRW	linear (RW)4-Dox	8	Linear	L	Doxorubicin (Dox) which is anthracycline attached with linker to CPP [W(RW)4 ]	Free	Free	Anticancer	Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP	HCT-116	Colon Cancer	MTT/MTS assay	21-61% antiproliferative activity at 1 µM	72 to 120-h	Colon	None
3161	23301519	2013	RWRWRWRW	linear (RW)4-Dox	8	Linear	L	Doxorubicin (Dox) which is anthracycline attached with linker to CPP [W(RW)4 ]	Free	Free	Anticancer	Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP	CCRF-CEM	Leukemia Cancer	MTT/MTS assay	46-69% antiproliferative activity at 1 µM	72 to 120-h	Blood	None
3162	23301519	2013	RWRWRWRW	linear (RW)4-Dox	8	Linear	L	Doxorubicin (Dox) which is anthracycline attached with linker to CPP [W(RW)4 ]	Free	Free	Anticancer	Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP	SK-OV-3	Ovarian Cancer	MTT/MTS assay	28-34% antiproliferative activity at 1 µM	72 to 120-h	Ovary	None
3160	23301519	2013	WRWRWRWRW	Cyclic [W(RW)4 ]-Dox	9	Cyclic	L	Doxorubicin (Dox) which is anthracycline attached with linker to CPP [W(RW)4 ]	Free	Free	Anticancer	Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP	MDA-MB-468	Breast Cancer	MTT/MTS assay	60-79% inhibition of cell proliferation at 1 µM	72 to 120-h	Breast	None
3156	23627474	2013	CHHNLTAAC	PTPRJ-pep19.7	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	20 ± 1.4% cell growth inhibition at 160 µM in 72 hours	72-h	Cervix	None
3157	23301519	2013	WRWRWRWRW	Cyclic [W(RW)4 ]-Dox	9	Cyclic	L	Doxorubicin (Dox) which is anthracycline attached with linker to CPP [W(RW)4 ]	Free	Free	Anticancer	Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP	CCRF-CEM	Leukemia Cancer	MTT/MTS assay	62-73% inhibition of cell proliferation at 1 µM	72 to 120-h	Blood	None
3158	23301519	2013	WRWRWRWRW	Cyclic [W(RW)4 ]-Dox	9	Cyclic	L	Doxorubicin (Dox) which is anthracycline attached with linker to CPP [W(RW)4 ]	Free	Free	Anticancer	Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP	SK-OV-3	Ovarian Cancer	MTT/MTS assay	51-74% inhibition of cell proliferation at 1 µM	72 to 120-h	Ovary	None
3159	23301519	2013	WRWRWRWRW	Cyclic [W(RW)4 ]-Dox	9	Cyclic	L	Doxorubicin (Dox) which is anthracycline attached with linker to CPP [W(RW)4 ]	Free	Free	Anticancer	Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP	HCT-116	Colon Cancer	MTT/MTS assay	50-67% inhibition of cell proliferation at 1 µM	72 to 120-h	Colon	None
3152	23627474	2013	CHHNATHAC	PTPRJ-pep19.5	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	2 ± 1.5% cell growth inhibition at 160 µM in 48 hours	48-h	Cervix	None
3153	23627474	2013	CHHNATHAC	PTPRJ-pep19.5	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	19 ± 4.2% cell growth inhibition at 160 µM in 72 hours	72-h	Cervix	None
3154	23627474	2013	CHHNLAHAC	PTPRJ-pep19.6	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	19 ± 4.2% cell growth inhibition at 160 µM in 72 hours	72-h	Cervix	None
3155	23627474	2013	CHHNLTAAC	PTPRJ-pep19.7	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	4.5 ± 2.13% cell growth inhibition at 160 µM in 48 hours	48-h	Cervix	None
3148	23627474	2013	CHANLTHAC	PTPRJ-pep19.3	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	51 ± 1.4% cell growth inhibition at 160 µM in 72 hours	72-h	Cervix	None
3149	23627474	2013	CHHALTHAC	PTPRJ-pep19.4	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	48.0 ± 2.82% cell growth inhibition at 160 µM in 24 hours	24-h	Cervix	None
3150	23627474	2013	CHHALTHAC	PTPRJ-pep19.4	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	62.5 ± 4.9% cell growth inhibition at 160 µM in 48 hours	48-h	Cervix	None
3151	23627474	2013	CHHALTHAC	PTPRJ-pep19.4	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	66.5 ± 2.12% cell growth inhibition at 160 µM in 72 hours	72-h	Cervix	None
3144	23627474	2013	CAHNLTHAC	PTPRJ-pep19.2	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	30 ± 2.82% cell growth inhibition at 160 µM in 48 hours	48-h	Cervix	None
3145	23627474	2013	CAHNLTHAC	PTPRJ-pep19.2	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	32.0 ± 4.2% cell growth inhibition at 160 µM in 72 hours	72-h	Cervix	None
3146	23627474	2013	CHANLTHAC	PTPRJ-pep19.3	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	28 ± 5.5% cell growth inhibition at 160 µM in 24 hours	24-h	Cervix	None
3147	23627474	2013	CHANLTHAC	PTPRJ-pep19.3	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	46 ± 4.2% cell growth inhibition at 160 µM in 48 hours	48-h	Cervix	None
3140	23627474	2013	CHHNLTHAC	PTPRJ-pep19	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	4.5 ± 0.1.4% cell growth inhibition at 160 µM in 48 hours	48-h	Cervix	None
3141	23627474	2013	CHHNLTHAC	PTPRJ-pep19	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	19 ± 2.82% cell growth inhibition at 160 µM in 72 hours	72-h	Cervix	None
3142	23627474	2013	CHHNLTHAC	PTPRJ-pep19.0	9	Linear	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	4 ± 1.4% cell growth inhibition at 160 µM in 72 hours	72-h	Cervix	None
3143	23627474	2013	CAHNLTHAC	PTPRJ-pep19.2	9	Cyclic(C1-C9)	L	None	Free	Free	Anticancer	PTPRJ agonist peptides	HeLa	Cervical Cancer	Trypan blue assay	16.5 ± 2.12% cell growth inhibition at 160 µM in 24 hours	24-h	Cervix	None
2874	23583573	2013	DEVD	caspase 3 inhibitor	4	Linear	L	None	Fluoromethyl ketone(fmk)	Free	Anticancer	caspase 3 inhibitor	Bcap-37	Breast Cancer	MTT/MTS assay	35 % Cell viability at 40 µM	1-h	Breast	None
2872	23583573	2013	DEVD	caspase 3 inhibitor	4	Linear	L	None	Fluoromethyl ketone(fmk)	Free	Anticancer	caspase 3 inhibitor	Bcap-37	Breast Cancer	MTT/MTS assay	65% Cell viability at 20 µM	1-h	Breast	None
2873	23583573	2013	DEVD	caspase 3 inhibitor	4	Linear	L	None	Fluoromethyl ketone(fmk)	Free	Anticancer	caspase 3 inhibitor	Bcap-37	Breast Cancer	MTT/MTS assay	40% Cell viability at 30 µM	1-h	Breast	None
2845	15634655	2004	ERRP	EGFR-related peptide	4	Linear	L	None	Free	Free	Anticancer	EGFR-related peptide	PC-3	Prostate Cancer	MTT/MTS assay	30% Cell viability at 5 µg/ml	48-h	Prostate	None
2802	None	2005	FALA	FLAK-120B	4	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ = >1000 µg/ml	24-h	Cervix	US_06875744_B2
2803	None	2005	WALAL	FLAK-120F	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ =302 µg/ml	24-h	Cervix	US_06875744_B2
2789	None	2005	FALLKL	FLAK96G	6	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ = >1000 µg/ml	24-h	Cervix	US_06875744_B2
2793	None	2005	KFKKLAKKF	Modelin-8D	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ = >1000 µg/ml	24-h	Cervix	US_06875744_B2
2794	None	2005	KFKKLAKKW	Modelin-8E	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ =510 µg/ml	24-h	Cervix	US_06875744_B2
2786	None	2005	FALALKALKKL	FLAK120	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ =400 µg/ml	24-h	Cervix	US_06875744_B2
2767	None	2005	FALALKA	FLAK94	7	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ = >1000 µg/ml	24-h	Cervix	US_06875744_B2
2771	None	2005	FALKALKK	FLAK97	8	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ =240 µg/ml	24-h	Cervix	US_06875744_B2
2756	None	2005	KAKLF	FLAK92	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ = >1000 µg/ml	24-h	Cervix	US_06875744_B2
2757	None	2005	KWKLF	FLAK93	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ = >1000 µg/ml	24-h	Cervix	US_06875744_B2
2754	None	2005	FAKLA	FLAK90	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ =700 µg/ml	24-h	Cervix	US_06875744_B2
2755	None	2005	FAKLF	FLAK91	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ =550 µg/ml	24-h	Cervix	US_06875744_B2
2704	None	2005	FAKLAKKLL	FLAK83M	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	HeLa	Cervical Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Cervix	US_06875744_B2
2660	None	2005	WALAL	FLAK-120F	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =570 µg/ml	24-h	Prostate	US_06875744_B2
2659	None	2005	FALA	FLAK-120B	4	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Prostate	US_06875744_B2
2651	None	2005	KFKKLAKKW	Modelin-8E	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Prostate	US_06875744_B2
2650	None	2005	KFKKLAKKF	Modelin-8D	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Prostate	US_06875744_B2
2646	None	2005	FALLKL	FLAK96G	6	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Prostate	US_06875744_B2
2643	None	2005	FALALKALKKL	FLAK120	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =340 µg/ml	24-h	Prostate	US_06875744_B2
2628	None	2005	FALKALKK	FLAK97	8	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Prostate	US_06875744_B2
2624	None	2005	FALALKA	FLAK94	7	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	Not Available	24-h	Prostate	US_06875744_B2
2614	None	2005	KWKLF	FLAK93	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Prostate	US_06875744_B2
2612	None	2005	FAKLF	FLAK91	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Prostate	US_06875744_B2
2613	None	2005	KAKLF	FLAK92	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Prostate	US_06875744_B2
2611	None	2005	FAKLA	FLAK90	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Prostate	US_06875744_B2
2561	None	2005	FAKLAKKLL	FLAK83M	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	PC-3	Prostate Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Prostate	US_06875744_B2
2516	None	2005	FALA	FLAK-120B	4	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Lung	US_06875744_B2
2517	None	2005	WALAL	FLAK-120F	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =370 µg/ml	24-h	Lung	US_06875744_B2
2508	None	2005	KFKKLAKKW	Modelin-8E	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Lung	US_06875744_B2
2507	None	2005	KFKKLAKKF	Modelin-8D	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Lung	US_06875744_B2
2503	None	2005	FALLKL	FLAK96G	6	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Lung	US_06875744_B2
2500	None	2005	FALALKALKKL	FLAK120	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =56 µg/ml	24-h	Lung	US_06875744_B2
2485	None	2005	FALKALKK	FLAK97	8	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Lung	US_06875744_B2
2481	None	2005	FALALKA	FLAK94	7	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Lung	US_06875744_B2
2471	None	2005	KWKLF	FLAK93	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Lung	US_06875744_B2
2470	None	2005	KAKLF	FLAK92	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Lung	US_06875744_B2
2469	None	2005	FAKLF	FLAK91	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =790 µg/ml	24-h	Lung	US_06875744_B2
2468	None	2005	FAKLA	FLAK90	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Lung	US_06875744_B2
2418	None	2005	FAKLAKKLL	FLAK83M	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	H-1299	Lung Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Lung	US_06875744_B2
2364	None	2005	WALAL	FLAK-120F	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =600 µg/ml	24-h	Skin	US_06875744_B2
2363	None	2005	FALA	FLAK-120B	4	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2355	None	2005	KFKKLAKKW	Modelin-8E	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2354	None	2005	KFKKLAKKF	Modelin-8D	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2350	None	2005	FALLKL	FLAK96G	6	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =590 µg/ml	24-h	Skin	US_06875744_B2
2347	None	2005	FALALKALKKL	FLAK120	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =240 µg/ml	24-h	Skin	US_06875744_B2
2332	None	2005	FALKALKK	FLAK97	8	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2317	None	2005	KAKLF	FLAK92	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2318	None	2005	KWKLF	FLAK93	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2328	None	2005	FALALKA	FLAK94	7	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =465 µg/ml	24-h	Skin	US_06875744_B2
2315	None	2005	FAKLA	FLAK90	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =330 µg/ml	24-h	Skin	US_06875744_B2
2316	None	2005	FAKLF	FLAK91	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2266	None	2005	FAKLAKKLL	FLAK83M	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2211	None	2005	FALA	FLAK-120B	4	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2212	None	2005	WALAL	FLAK-120F	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =600 µg/ml	24-h	Skin	US_06875744_B2
2202	None	2005	KFKKLAKKF	Modelin-8D	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2203	None	2005	KFKKLAKKW	Modelin-8E	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2198	None	2005	FALLKL	FLAK96G	6	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =590 µg/ml	24-h	Skin	US_06875744_B2
2195	None	2005	FALALKALKKL	FLAK120	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =240 µg/ml	24-h	Skin	US_06875744_B2
2180	None	2005	FALKALKK	FLAK97	8	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2176	None	2005	FALALKA	FLAK94	7	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =465 µg/ml	24-h	Skin	US_06875744_B2
2165	None	2005	KAKLF	FLAK92	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2166	None	2005	KWKLF	FLAK93	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2163	None	2005	FAKLA	FLAK90	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =330 µg/ml	24-h	Skin	US_06875744_B2
2164	None	2005	FAKLF	FLAK91	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2114	None	2005	FAKLAKKLL	FLAK83M	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	BMKC	Skin Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Skin	US_06875744_B2
2059	None	2005	FALA	FLAK-120B	4	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Colon	US_06875744_B2
2060	None	2005	WALAL	FLAK-120F	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =440 µg/ml	24-h	Colon	US_06875744_B2
2051	None	2005	KFKKLAKKW	Modelin-8E	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =70 µg/ml	24-h	Colon	US_06875744_B2
2050	None	2005	KFKKLAKKF	Modelin-8D	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Colon	US_06875744_B2
2046	None	2005	FALLKL	FLAK96G	6	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Colon	US_06875744_B2
2043	None	2005	KWKKLAKKW	FLAK120	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =240 µg/ml	24-h	Colon	US_06875744_B2
2028	None	2005	FALKALKK	FLAK97	8	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Colon	US_06875744_B2
2024	None	2005	FALALKA	FLAK94	7	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =560 µg/ml	24-h	Colon	US_06875744_B2
2014	None	2005	KWKLF	FLAK93	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =555 µg/ml	24-h	Colon	US_06875744_B2
2013	None	2005	KAKLF	FLAK92	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Colon	US_06875744_B2
2012	None	2005	FAKLF	FLAK91	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =550 µg/ml	24-h	Colon	US_06875744_B2
2011	None	2005	FAKLA	FLAK90	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =530 µg/ml	24-h	Colon	US_06875744_B2
1962	None	2005	FAKLAKKLL	FLAK83M	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	SW-480	Colon Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Colon	US_06875744_B2
1908	None	2005	WALAL	FLAK-120F	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =260 µg/ml	24-h	Breast	US_06875744_B2
1907	None	2005	FALA	FLAK-120B	4	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Breast	US_06875744_B2
1899	None	2005	KFKKLAKKW	Modelin-8E	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Breast	US_06875744_B2
1898	None	2005	KFKKLAKKF	Modelin-8D	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Breast	US_06875744_B2
1894	None	2005	FALLKL	FLAK96G	6	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =630 µg/ml	24-h	Breast	US_06875744_B2
1891	None	2005	FALALKALKKL	FLAK120	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =360 µg/ml	24-h	Breast	US_06875744_B2
1876	None	2005	FALKALKK	FLAK97	8	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Breast	US_06875744_B2
1872	None	2005	FALALKA	FLAK94	7	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =430 µg/ml	24-h	Breast	US_06875744_B2
1862	None	2005	KWKLF	FLAK93	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =600 µg/ml	24-h	Breast	US_06875744_B2
1861	None	2005	KAKLF	FLAK92	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Breast	US_06875744_B2
1860	None	2005	FAKLF	FLAK91	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Breast	US_06875744_B2
1859	None	2005	FAKLA	FLAK90	5	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =500 µg/ml	24-h	Breast	US_06875744_B2
1810	None	2005	FAKLAKKLL	FLAK83M	9	Linear	L	None	Amidation	Free	Anticancer	FLAK peptides	MCF-7	Breast Cancer	MTT/MTS assay	LD₅₀ =>1000 µg/ml	24-h	Breast	US_06875744_B2
1548	18656352	2008	RKKRRQRRR	Tat	9	Linear	L	None	Free	Free	Anticancer	HIV-Tat (49-57)	HCT-116	Colon Cancer	MTT/MTS assay	~10% Cytotoxicity at 100 µM	24-h	Colon	None
7788	None	2023	WKWLKKWIK	AMP1	9	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	OVCAR-3	Ovarian Cancer	MTT assay	IC₅₀ = 51.1 μM	48-h	Ovary	US11571454 B2
7789	None	2023	KRWWKWWRR	AMP2	9	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	OVCAR-3	Ovarian Cancer	MTT assay	IC₅₀ = 53.5 μM	48-h	Ovary	US11571454 B2
7808	None	2022	YKSIEFC	P1C	7	Linear	L	None	Acetylation	Free	Anticancer	Synthetic	BXPC-3	Pancreatic Cancer	Cell Proliferation assay	~40% reduction in cell growth at 20 μM	72-h	Pancreas	US011214593B2
7809	None	2022	YKSIEFC	P1A	7	Linear	L	None	Free	Free	Anticancer	Synthetic	BXPC-4	Pancreatic Cancer	Cell Proliferation assay	~50% reduction in cell growth at 20 μM	72-h	Pancreas	US011214593B2
7810	None	2022	YKSVEFC	P1B	7	Linear	L	None	Acetylation	Free	Anticancer	Synthetic	BXPC-5	Pancreatic Cancer	Cell Proliferation assay	~50% reduction in cell growth at 20 μM	72-h	Pancreas	US011214593B2
7851	29580912	2018	ywNTF(AzGly)R(Me)W	TAK-448	8	Linear	Mix	aza-glycine; Me=Methylation	Amidation	Acetylation	Anticancer	Synthetic	VCaP	Prostate Cancer	Given i.h.; dosings on day 0 and 28	Had greater anti-tumor effects in VCaP xenograft model	28 days	Prostate	None